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  1. Summary 
 
The study of adeno-associated virus (AAV) has a dual importance for research and 
therapeutic applications: as a nonpathogenic virus that can interact in a co-infection with 
its helper virus in order to replicate and as a widely used viral vector for gene therapy. 
Although both sides have been extensively studied, many questions still remain to be 
answered. 
The two aims of my PhD study tackled this dual facet by investigating (i) the 
performance of single-stranded (ss) and double-stranded (ds), self-complementary (sc) 
AAV vectors in transducing cells and (ii) the replication of wild type (wt) AAV2 in co-
infection with HSV-1. 
Concerning the first Specific Aim, we showed that HSV-1 provided helper functions do 
not allow AAV2 to replicate in different phases of the cell cycle. AAV2 and HSV-1 
replicate in different sets of cells. In particular, AAV2 replication as well as gene 
expression from both single-stranded (ss) and self-complementary (sc) AAV2 vectors 
preferentially occurs in S/G2 cell cycle phase cells. Moreover, the ss and scAAV vectors 
can differentially affect the cell cycle progression. In a multifluorescence live cell 
microscopy assay we observed that the vast majority of transduced cells were in S/G2 
phases of the cell cycle independent of the genome structure ss or sc or the presence 
or absence of HSV-1. We therefore hypothesized that second-strand synthesis is likely 
not responsible for the cell cycle preference of AAV2 replication/gene expression. 
In the second Specific Aim, we performed a high-throughput image-based siRNA 
screening of 62 cellular factors previously identified as components of AAV2 replication 
compartments in human cervical carcinoma cell line (HeLa ATCC cells) to identify their 
roles in ss and sc AAV vector transduction. Some cellular proteins were found to inhibit 
(e.g. Mre11, NBN, Rad50, MSH3, PCNA) or enhance (e.g. EEF1A1) transduction by 
both ss and ds AAV vectors. Other proteins appeared to enhance or inhibit transduction 
by one vector but did not have an effect on the other vector; for example, the 
knockdown of replication factor 2 (RFC2) inhibited the infection rate of the ss AAV 
vector but had no effect on that of the sc AAV2 vector. An interesting group of proteins 
includes replication protein A 1 (RPA1) and mismatch repair proteins MSH2 and MSH6, 
where siRNA knockdown led to opposite effects for ss and sc AAV vectors. The role of 
RPA1 and RPA2, which together with RPA3 form the heterotrimeric RPA complex, was 
3
	  further investigated by posttranscriptional knockdown of endogenous and 
complementation with exogenous genes. These assays revealed that RPA1 and RPA2 
both had a differential effect on the transduction efficiencies of the ss and ds AAV 
vectors and that only RPA2 enhanced HSV-1 supported AAV2 replication, while RPA1 






























	  2. Zusammenfassung 
 
Das Adeno-asoziierte Virus (AAV), ein Dependoparvovirus innerhalb der Familie der 
Parvoviridae, hat eine doppelte Signifikanz, einerseits für die Virusforschung und 
andererseits für therapeutische Anwendungen. AAV ist ein replikations-defektes, 
nichtpathogenes Virus, das nur in Anwesenheit eines Helfervirus replizieren kann. 
Gleichzeitig ist AAV ein weit verbreiteter Virusvektor für die Gentherapie. Obwohl beide 
Aspekte eingehend untersucht wurden, gibt es noch viele Fragen zu beantworten.   
Die Ziele meiner Doktorarbeit waren (i) die Effizienz von einzelsträngigen (ss) und 
doppelsträngigen (ds), selbst-komplementären (sc) AAV-Vektoren bei der Transduktion 
von Wirtszellen und (ii) die Replikation von Wildtyp (wt) AAV2 in Co-Infektion mit HSV-1 
zu untersuchen.   
Im ersten Teil haben wir gezeigt, dass AAV2 Replikation und Genexpression Zellzyklus 
abhängig ist und in der S/G2 Phase stattfindet. Dies wiederum führt dazu, dass das 
Helfervirus nun hauptsächlich in G1 Zellen repliziert. In ko-infizierten Kulturen 
replizieren AAV2 und HSV-1 also in verschiedenen Zellen, die sich in ihrem Zellzyklus 
unterscheiden. Interessanterweise ist nicht nur die Genexpression von ss 
rekombinanten (r) AAV Vektoren Zellzyklus abhängig, sondern auch jene de sc AAV 
Vektoren. Erstaunlicherweise können die ss- und scAAV-Vektoren den Zellzyklusverlauf 
unterschiedlich beeinflussen: ssAAV Vektoren induzieren einen Zellzyklus-Stop 
während scAAV Vektoren die Progression des Zellzyklus erlauben. 
Im zweiten Teil haben wir ein siRNA-Screening von 62 zellulären Faktoren 
durchgeführt, die zuvor als Komponenten von AAV2-Replikations Kompartimenten 
identifiziert wurden, um deren Effekt auf die Transduktion von ss- und sc-AAV-Vektoren 
zu untersuchen. Dabei haben wir Proteine identifiziert, welche die Transduktioneffizienz 
sowohl von ss als auch von sc-AAV-Vektoren verkleinern (z. B. Mre11, NBN, Rad50, 
MSH3, PCNA) oder erhöhen (z. B. EEF1A1). Andere Proteine schienen die 
Transduktionseffizienz eines Vektors zu verstärken oder zu inhibieren, hatten aber 
keinen Effekt auf den anderen Vektor. So hemmte zum Beispiel der Knockdown von 
RFC2 die Transduktionsrate des ss-AAV-Vektors, hatte aber keine Auswirkung auf die 
des sc AAV2-Vektors. Eine interessante Gruppe von Proteinen wie RPA1, MSH2 und 
MSH6, hatte einen entgegengesetzten Einfluss auf die Transduktionseffizienz  von ss- 
und sc-AAV-Vektoren. Die Rolle von RPA1 und RPA2, die zusammen mit RPA3 den 
5
	  heterotrimeren RPA-Komplex bilden, wurde durch den posttranskriptionellen 
Knockdown von endogenen und Komplementierung mit exogenen RPA Genen weiter 
untersucht. Diese Experimente zeigten, dass RPA1 und RPA2 beide einen 
differentiellen Effekt auf die Transduktionseffizienzen der ss- und ds-AAV-Vektoren 
hatten, dass aber nur RPA2 die HSV-1-unterstützte AAV2-Replikation verstärkte, 
während RPA1 keine signifikante Wirkung auf die AAV2-DNA-Replikation hatte. 
Insgesamt ermöglicht diese Arbeit ein besseres Verständnis der komplexen und 
































	  3. Introduction 
 
3.1. Adeno-associated virus type-2 (AAV2) and its helper virus herpes 
simplex virus type-1 (HSV-1) 
 
3.1.1. AAV biology, structure and genome organization 
 
Adeno-associated virus (AAV) belongs to the genus Dependoparvovirus within the 
family of the Parvoviridae. It is a non-enveloped, non-pathogenic, helper-dependent 
virus with a single-stranded (ss) DNA genome of approximately 4.68 kb and a size of 25 
nm in diameter. It was initially found as a contaminant of human adenovirus (Ad) 
isolates in cell cultures (1). AAV induces low immune responses in comparison to other 
viruses (2). There are more than twelve human serotypes described, 100 from 
nonhuman primates (3) with different tissue tropism (4–6) and several others from 
avian, bovine, avian canine and equine species. Endogenous AAV sequences were 
predominantly found in liver, bone marrow and spleen (7), as well as in tonsils and 
adenoids in children (8).  It is believed that most probably AAV enters via oropharynx 
together with adenovirus that acts as a helpervirus in the replication process. After 
several rounds of replication and dissemination to different tissues, the host immune 
system will finally inhibit the infectious process (8).   
The AAV serotype 2 (AAV2) was the first discovered infectious clone (9) with high ability 
to transduce common cell lines such as HeLa or HEK-293T (10), and it has 
continuously been the most extensively studied virus of all AAV serotypes.  
The AAV2 genome is a linear single-stranded DNA and encodes two clusters of genes, 
rep and cap, that are flanked by inverted terminal repeats (ITRs) of 145 nucleotides 
(11–13). The rep gene cluster encodes four Rep proteins: two large required for DNA 
replication, Rep68 and Rep78, and two small Rep proteins, Rep40 and Rep52, involved 
in gene expression and packaging (14, 15). The cap gene is controlled by the p40 
promoter and encodes three capsid proteins VP1, VP2, VP3 which, due to alternative 
start codons, differ in their N-termini (16, 17). The assembly-activating protein (AAP) 
that is required for AAV2 capsid assembly in the nucleolus, is encoded in a nested open 
reading frame within the cap gene (18). The crystal and genomic structure of AAV2 are 





3.1.2. AAV2 intracellular transport 
 
AAV2 attachment and entry 
 
AAV2 requires a primary glycan receptor, first identified as heparin sulfate proteoglycan 
(HSPG) for AAV2 (19), together with a co-receptor for optimal attachment and 
internalization such as fibroblast growth factor receptor 1 (FGFR1) (20), hepatocyte 
growth factor receptor (MET) (21), laminin receptor (22), integrin αVβ5 (23), integrin 
α5β1 (23). Nevertheless, some of these receptors failed to be confirmed in other studies 
(24, 25). Recently it was discovered, via a genetic screening in human haploid cells, a 
new key host receptor for AAV infection both in vitro and in vivo, AAV receptor (AAVR), 
previously known as the type I transmembrane protein, KIAA0319L, that presented 
strong capabilities of endocytosis from the plasma membrane and trafficking to the 
trans-Golgi network (25). 
AAV2 internalization can take about 30 minutes and occurs via endocytosis (26). 
Several pathways have been reported to be involved in AAV2 endocytosis, such as 
clathrin-mediated uptake (26, 27), Rac1-mediated and PI3 kinase activation cascade 
(28), or the recently characterized clathrin-independent carriers/GPI-enriched endocytic 
compartment (CLIC/GEEC) pathway (29). Di Pasquale and colleagues, showed that 
only intact AAV4, AAV5 or BAAV viral particles applied on the apical side of polarized 
cells can cross by transcytosis process (30, 31).  
AAV2 intracellular trafficking and nuclear import 
The majority of AAV2 particles will accumulate in the perinuclear region, whereas only 
few will access the nucleus, as demonstrated in an in vitro assay (26). Transport steps 
were found to be involving Golgi apparatus for AAV2 and AAV5 virions or late 
endosomes enriched in Rab7 and Rab11 for fractions of AAV2 particles (32–34). 
Endosomal processing exposes the VP1 and VP2 N-terminal domains outside of the 
capsid which allows an efficient viral transduction (18, 35).  
Intact virions can be apparently detected inside the nucleus (26, 28, 36), and they can 
be as well recovered as fully infectious particles (37, 38). However, Sonntag and 
colleagues reported an inefficient and rate-limiting AAV2 nuclear import, based on poor 
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  infectivity of virions with exposed VP1/2 N-termini following cytoplasmic injection (18). 
To have more insight into the mechanisms of the transport to the nucleolus, some 
studies reported that AAV2 capsids can interact with nucleolin or B23/nucleophosmin 
(38–40). The kinetics of DNA release showed a cell-type dependency, as in HeLa cells 
it was less efficient for AAV6 than for AAV2 with AAV6 more efficient in cardiac cells 
(41, 42). Duan et al. (42) and Yan et al. (43) showed that proteasome inhibitors can 
increase AAV trafficking to the nucleus, suggesting that capsid ubiquitination may play a 
role in AAV transduction.  
3.1.3. AAV2 DNA replication  
For productive replication, AAV2 depends not only on a cell but on a helper virus, such 
as herpes simplex virus type 1 (ref), adenovirus 2 (AdV2), or human papillomavirus 
(HPV) 16 (44–46). Not only alphaherpesviruses, such as HSV-1 and HSV-2 (44), but 
also betaherpesviruses, including human cytomegalovirus (HCMV) (47) and human 
herpes virus 6 (HHV6) (48), can act as helper viruses for AAV2 replication. However, of 
all herpes viruses that can act as helper viruses for AAV2 replication, HSV-1 is the best 
characterized.  
The unique replication strategy of AAV2 is based on a rolling-hairpin mechanism in 
which the 3’-ITR acts as essential primer for second-strand synthesis (49). Replication 
of AAV2 was also demonstrated in several cell lines upon genotoxic stress (50, 51). 
AAV2 can also replicate autonomously in cultured differentiating keratinocytes (52). The 
helper functions have been well studied and are well characterized for both Ad and 
HSV-1. The following Ad genes provide helper functions for AAV2 replication:  E1a, 
E1b, E2a, E4 and the VA RNA (53); The HSV-1 proteins required for AAV2 replication 
include: UL30/42, UL9, UL5/8/52 (helicase-primase) and UL29 (ssDBP also known as 
ICP8) (reviewed in (54)). Alazard-Dany et al. (55) showed that the herpesvirus 
regulatory proteins ICP0, ICP4 and ICP22, although not essential, can also enhance 
AAV2 DNA replication. Moreover, ssDNA-binding protein ssDBPs of Ad (Ad-DBP), 
HSV-1 (ICP8) and the cell (RPA) enhance binding and nicking of Rep proteins at the 
origin of DNA replication (56), which consist of Rep binding elements (RBE and RBE’) 
and a terminal resolution site (TRS) and are located within the ITRs (3).  
AAV2 DNA replication occurs in intranuclear replication compartments (RCs) that 
colocalize with Rep protein (56–58). The RCs were found associated with promyelocytic 
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  leukemia (PML) nuclear bodies (NBs) in the case of AAV2 and AdV coinfection but not 
when HSV-1 was used as helper virus (57).  
 
Cellular factors and AAV2 DNA replication 
 
          There are two important proteomics studies that revealed the complexity of AAV2 
replication and interactions with the host cell machinery. In the first study, Nash and 
colleagues (59) used a tandem affinity purification approach in cells coinfected with 
AAV2 and AdV5 to identify 188 cellular proteins from 16 functional categories involved 
in DNA repair and replication, transcription, translation, protein degradation and RNA 
splicing. In the second proteomic study, Nicolas and colleagues (60) elucidated which 
cellular and HSV-1 factors are recruited within RCs and associated with Rep protein. 
The proteins identified were functionally classified into the main categories of DNA and 
RNA metabolism or associated to cytoskeleton and mitochondrial structures. Thus, 
components of the DNA replication machinery such as RPA, RFC, MCM or PCNA were 
shown to be recruited into HSV-1-induced AAV RCs and to colocalize with Rep protein. 
Moreover, some of the proteins and functional categories were found to be similar to the 
ones discovered in the AdV-dependent AAV2 replication compartments reported in the 
first proteomics screen. As shown in Fig. 2 different interactions and networks between 
the discovered Rep-associated proteins were suggested (60). The viral and cellular 
proteins found in AAV2 RCs were further reviewed and discussed in Vogel et al (61). 
Importantly, the results of these studies constituted the base of Specific Aim 2 of this 
PhD project and will be described in more detail in chapters 5.1 and 5.2. 
Further reports showed that purified cellular factors RPA, PCNA and RFC and a 
partially purified cellular DNA polymerase fraction were necessary for AAV2 DNA 
replication (62).  
 
Viral factors and AAV2 DNA replication 
 
AAV2 relies primarily on cellular replication proteins when coinfected with AdV, as Ad 
DNA replication proteins such as Ad DNA polymerase, Ad terminal protein and Ad DBP 
did not show a significant effect on AAV2 replication (63, 64). In contrast, in the case of 
coinfection with HSV-1, the expression of single-stranded DBP, UL9 and the helicase-
primase complex, UL5/UL8/UL22, is required for AAV2 DNA replication (65, 66).  
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  The ss DBPs Ad DBP, UL29 and RPA2 were found to colocalize in infected cell nuclei 
with AAV Rep protein and AAV DNA (57, 67). Moreover, the interaction between these 
DBPs and Rep protein enhanced AAV DNA replication up to five-fold through enhanced 
processivity (49, 68) and site-specific endonuclease activity at the trs (56). 
 
3.1.4. AAV2 integration  
 
In absence of a helper virus, AAV2 enters latency. Its gene expression program is auto-
repressed and the genome is integrated into the host cell genome, preferentially into a 
region on the long arm of human chromosome 19 (19q13.3-qter) designated AAVS1 
(69–71). This very well characterized locus was found in the vicinity of the muscle-
specific genes p85, TNNT1 and TNNI (69, 72, 73), in a transcription-competent 
chromosomal region (74). The AAV components required for its integration are the ITRs 
in cis, Rep78 or Rep68 in trans and an integration efficiency element (IEE) located 
within the p5 promoter in cis (75). The AAV2 genome can also persist as an episome in 
the cell nucleus (71). 
 
3.1.5. Recombinant AAV vectors, limitations of their cellular transduction and 
gene therapy applications 
 
 
AAV is one of the most frequently used viral vectors in gene therapy due to its absence 
of pathogenicity, ability to express transgenes for long time periods, low 
immunogenicity, efficient transduction of postmitotic cells and general lack of toxicity (3, 
76, 77). The most widely used recombinant AAV vectors belong to the serotype 2 and 
include ss and ds, sc vectors. The scAAV vectors have a smaller transgene capacity 
and a higher transduction efficiency both in vitro and in vivo, due to bypassing the 
second-strand synthesis step that has been identified as a rate-limiting element in AAV 
gene expression (15, 78, 79), as shown in Fig. 3. The DNA hairpin structures of ss 
recombinant (r)AAV vectors can attract Mre11 and ATM proteins involved in ds break 
repair (80, 81). However, Fragkos and colleagues (82) demonstrated that rAAV2 
vectors without p5 promoter do not provoke a DNA damage response of a stalled 
replication fork.  
The mechanisms of AAV transduction in cells and tissues still remain unclear. However, 
in several publications it was shown that transduction of cells with recombinant AAV 
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  vectors could be increased by genotoxic agents and DNA damaging treatment (83, 84), 
and negatively influenced by ATM kinase (85) and proteins of the MRN complex (86, 
87).  
Target diseases for AAV vector mediated gene therapy include monogenic disorders 
such as cystic fibrosis (88), hemophilia (89), or others such as rheumatoid arthritis (90), 
spinal muscular atrophy (91) and Parkinson’s disease (92). The first AAV gene therapy-
based vector product that has received marketing authorization under exceptional 
circumstances in Europe in 2012 is alipogene tiparvovec (Glybera®), which is used for 
the treatment of patients with lipoprotein lipase deficiency (LPLD) (93–95). This was a 
significant step forward for numerous AAV gene therapy applications and gave further 
hope and great perspectives for using this virus as an effective therapeutic agent.  
 
3.1.6. HSV-1 biology: structure, life cycle and DNA replication 
 
HSV-1 pathogenesis and genome structure  
Herpesviruses, belonging to the family of the Herpesviridae, are large double-stranded 
DNA viruses. There are eight different human herpesviruses known to date. All 
herpesviruses can establish both lytic infections at the site of entry and latent infections. 
HSV-1 for example can establish latency in sensory ganglia. Studies of latently infected 
mouse ganglia have revealed HSV-1 DNA in 1–30% of neurons (96–99).  
HSV-1 and HSV-2 are human pathogens that can cause vesicular to ulcerative lesions 
on mucosal epithelium, skin or cornea. In some cases encephalitis can rarely occur in 
children or adults, whereas newborn infants can suffer from severe disseminated 
disease (100).  
The pleomorphic herpesvirus particle is approximately 300nm in diameter and is 
composed of the DNA core, an icosahedral capsid, a tegument and an envelope 
consisting of a lipid bilayer containing viral membrane proteins and glycoproteins (Fig. 
4A). The viral envelope contains 11 viral glycoproteins which play a role in viral entry 
(101, 102). Virus-encoded proteins form the tegument with primary role in initial steps of 
infection such as trafficking to the nucleus, inhibition of cellular gene expression and 
initiation of viral gene expression (103). HSV-1 proteins expressed from the genes 
UL18, UL19, UL26, UL26.5, UL35, UL38 and UL6 (104) constitute the capsid. 
12
	  The 152-kb linear double-stranded HSV-1 genome encodes more than 90 proteins and 
is divided into unique long (UL) and unique short (US) regions which are both flanked by 
inverted repeats (100, 105). Seven virus proteins are important for viral DNA replication 
including the components of helicase-primase complex, the origin-specific DNA-binding 
protein (OBP), the ssDBP (ICP8), the DNA polymerase and accessory factor (106, 107). 
The origins of DNA replication are present within the unique longue region (oriL) and 
within the c repeats bounding the unique short region (oriS) (94). oriL and oriS contain 
regions rich in A/T flanked by recognition sites for origin-binding proteins OBPI, OBPII 
and UL9 (108). DNA packaging signals (pac) are found at the ends of the genome and 
at the junction between the long and the short segment (109). (Fig. 4B) 
HSV-1 entry 
Binding of HSV-1 to cells is mediated principally by viral envelope glycoprotein gC 
protein, secondarily by gB and gD proteins that could as well substitute for gC. Virus 
entry requires fusion of the virion envelope with the cell membrane and depends on the 
action of gB, gD, gH, and gL (99, 100). gC and gB can bind to heparan sulfate 
proteoglycans (HSPGs) which can further promote the attachment of HSV-1 to the cell 
(103).  
The first HSV entry receptor identified was originally named herpesvirus entry mediator 
(HVEM) (110), later renamed as herpesvirus entry protein A (HveA) (111) and then 
catalogued as TNFRSF14. Additional human entry receptors HveC and HveB were then 
described (112) and proved to be related members of the immunoglobulin superfamily 
(111, 113).  
The entry process occurs via direct fusion of the plasma membrane either with the viral 
envelope or with the intracellular vesicle after endosomal or phagosomal uptake of the 
virus (114, 115, 116). Nicola et al (117) showed that the predominant entry pathway of 
HSV into the chinese hamster ovary cells CHO-K1 and HeLa cells can be strongly 
affected by a low pH and endocytosis, suggesting that, following to one or multiple 
receptor binding, HSV can use two different entry pathways depending of the cell type. 
The fusion process requires the glycoprotein complex including gB, gD and gH/gL (103) 
and cellular receptors such as nectin-1 or nectin-2 in epithelial cells and neurons, HVEM 
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  in fibroblasts and retinocytes or 3-O sulfated heparan sulfate in corneal fibroblasts 
(118).  
HSV-1 transcription and DNA replication 
After fusion of the virion envelope and the cell membrane and the transport of the viral 
nucleocapsid along microtubules, the viral genome is released into the nucleus through 
the nuclear pores. The linear HSV-1 DNA is then circularized and transcribed in three 
kinetic phases including immediate-early (IE), early (E) and late (L) genes (117). IE and 
E genes encode for proteins necessary for the gene expression and DNA replication, 
whereas proteins encoded by L genes are required for virus assembly and egress 
(119). L genes can be divided in leaky late, that become upregulated at later times of 
infection, and true late expressed only after viral DNA replication started (101). The 
HSV-1 genes are transcribed by the host RNA polymerase II (101). Initiation of gene 
expression depends on histone demethylation associated with viral DNA after nuclear 
entry, mediated by lysine-specific demethylase 1 (LSD1) (120). 
HSV-1 DNA replication and gene expression  occurs in nuclear compartments that form 
in the proximity of promyelocytic leukemia nuclear bodies (PML NBs) (121). IE gene 
products expressed 2-4 hours after infection include ICP0, ICP4, ICP22, ICP27 and 
ICP47. VP16, an HSV-1 tegument protein contains an acidic activator domain and 
activates the transcription of IE genes in concert with cellular transcription factors (122). 
VP16 and host cell factor (HCF) form a complex within the nucleus that binds to the 
host transcription factor octamer-binding protein 1 (OCT1) (122). IE gene products in 
turn transactivate the transcription of the E genes. For example, ICP4 has the ability to 
regulate gene expression by forming a tripartite complex with TATA-binding protein and 
TFIIB (123). The E gene products constitute proteins involved in DNA metabolism which 
signal the onset of viral DNA replication. DNA replication is followed by the synthesis of 
the L proteins which include the structural components of the virus.  
VP16, ICP0 and Us3 (unique S component open reading frame 3) have been involved in 
the control of chromatin structure of HSV lytic genes (reviewed in (124, 125)). From this, 
ICP0 is a viral gene that is responsible not only for the lytic replication but also for 
reactivation from latency. ICP0 as a transactivator of all three kinetic phases of HSV-1 
genes and contains several key domains: the N-terminal RING-finger domain, the C-
14
	  terminal ND10 localization signal (126, 127), a dimer/multimer motif (128) and a binding 
site for ubiquitin-specific protease 7 (USP7) (129).  
HSV-1 DNA replication requires either oriS or oriL and the initiator protein UL9. It 
initiates as a origin-dependent theta replication, followed by a predominant origin-
independent rolling-circle mechanism (130, 131). The essential HSV-1 replication genes 
are located within UL and include: UL5, UL8, UL9, UL29 (its product is ICP8, the single-
strand DNA-binding protein), UL30 (DNA polymerase), UL42 and UL52 (131–133). The 
rolling circle replication model was reconstituted in vitro by extracts of HSV-1 infected 
cells (134). 
HSV-1 egress 
In both epithelial cells and neurons the directed spread of the virus is highly dependent 
on the transmembrane glycoprotein gE (reviewed in (135)). Virus lacking gE presented 
a limited and less efficient spread in vivo.  
The nuclear egress complex (NEC) of herpesviruses is essential for nuclear budding 
and is composed of viral proteins UL31 and UL34 (136, 137). Formation of the NEC is 
required for the localization of both UL31 and UL34 in the inner nuclear membrane 
(INM), for the recruitment of viral and cellular kinases with role in modification of host 
cell chromatin and nuclear lamina and for efficient nuclear egress of nucleocapsids 
(reviewed in (135, 136, )). Modifications of the INM shape around the capsid have been 
described (138). Importantly, Hagen et al (139) used a multimodal imaging approach to 
visualize the NEC in situ forming coated vesicles and reported the identification via 
cellular electron cryo-tomography of a protein layer with two hexagonal lattices at the 
proximal and distant membrane faces. However, it was shown that the NEC is sufficient 
to induce vesiculation of the nuclear envelope in transfected cells (140). A recent report 
suggested that NEC can function as minimal virus-encoded membrane-budding 














Figure 1. AAV2 virion and genome structure. 
(A) Electronmicrograph (approximately 20 nm virions) and crystal structure of the AAV capsid 
with VP3 hypervariable regions coloured to the matching genetic regions. The 
electronmicrograph is courtesy of E. Schraner, Institute of Virology, University of Zurich. Bar: 
100nm. 
(B) The AAV2 genome contains two clusters of genes flanked by T-shaped hairpins at each 
end forming the inverted terminal repeats (ITRs). The four non-structural proteins (Rep40, 
Rep52, Rep68 and Rep78) are encoded by the rep genes, whereas the structural proteins 
(VP1, VP2, and VP3) that form the viral capsid are encoded by the cap genes. The 
assembly-activating protein (AAP) is encoded by an alternative ORF within cap. Coloured 
arrows: hypervariable regions.  
Figure from Kotterman MA and Schaffer DV, 2014, Nature Reviews Genetics 15:445-451 










Figure 2.  Schematic map of interaction networks of Rep-associated proteins 
found in AAV and either HSV-1 or AdV co-infected cells.  
The color codes refer to the protein specific interactions identified from HeLaAAVtCR 
cells infected with wt HSV-1 (red), HSV1UL30 (yellow), or both helper viruses (orange); 
proteins for which a physical or functional interaction with a protein from another virus 
has already been reported (green); self-interacting proteins (black); proteins identified in 
Rep-containing complexes purified from adenovirus- and AAV-coinfected cells 
(asterisks); proteins constituting a known functional complex (dashed brown circles).  







Figure 3. Comparison between recombinant ss (rAAV) and ds (scAAV) vectors.  
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Figure 4. HSV-1 structure and genome organization 
(A) Electronmicrograph and schematic representation of the HSV-1 particle. 
The diameter of the whole particle varies between 200 and 300 nm. The 
electronmicrograph is courtesy of E. Schraner, Institute of Virology, University of Zurich. 
Bar: 100 nm.  
(B) The HSV-1 genome is composed of two distinct segments, unique long (UL) and 
unique short (US) and terminal and internal inverted repeats of the long (L) and short 
(S) segments (TRL, IRL, IRS, TRS). The origins of DNA replication (oriL and oriS) and 
the DNA packaging/cleavage signals (pac) are the sole cis elements required for DNA 
replication and packaging.  
 





	  3.2. Viruses and the cell cycle 
 
The cell cycle is driven through the four stages G1, S, G2 and mitosis by kinase 
complexes formed by cyclins bound to cyclin-dependent kinases (Cdk). The levels of 
regulation are achieved by Cdc25 family of protein phosphatases (142) and the small 
inhibitory proteins  CDK-inhibitors (CKIs). During G2, cyclin B1 forms a kinase complex 
with Cdk1 that remains inactive and can be further catalyzed by a nuclear protein Wee1 
(143). In late G2, the kinase complex is activated by Cdc25C that is regulated through 
phosphorylation of Cdk1. Importantly, Cdk1/cyclin B1 complex can be inactivated by the 
anaphase-promoting complex (APC)  possibly by degrading cyclin B1 (144).  
During S phase, cyclin A functions with Cdk2 to phosphorylate pre-replication 
complexes to ensure that only one single round of DNA replication occurs. G2/M 
transition and exit from mitosis are regulated by various kinases and phosphatases 
(145, 146) whereas  the activation of checkpoints is controlled mainly by ATM and ATR 
kinases. ATM and ATR initiates the phosphorylation cascade from Chk2 to Wee1 to 
Cdk1 leading to their activation and phosphorylation of Cdc25C (147–149).The 
checkpoint pathways can maintain Cdk1/cyclin B1 complexes inactive and prevent their 
nuclear accumulation. Moreover, the induction of G2 arrest is regulated by p53 that, by 
controlling p21, can lead to the inhibition of the kinases’ activity (145).  
Viruses can manipulate the cell cycle progression and alter checkpoint signaling in 
order to provide a proper environment for their replication (150, 151). 
One of the common strategies used by viruses such as retroviruses, DNA and RNA 
viruses, is to induce cell cycle arrest at G2/M (reviewed in (152)). Other viruses, like 
oncogenic viruses, manipulate the  cell cycle transition in G1/S via p53 inactivation 
(reviewed in (153)). However, many viruses can interplay with all phases of the cell 
cycle. Here an overview of possible molecular mechanisms underlying these strategies 
of interaction with viral proteins and cell cycle factors is described.  
G2/M arrest is achieved by either inactivation of Cdk1 at the G2/M checkpoint and/or 
interference with mitotic progression. Human papillomavirus (HPV) type 1 E4 protein  
can induce G2 arrest by maintaining the Cdk1 phosphorylation that will finally result in a 
delay of Cdk1/cyclin B1 kinase activation (154, 155). The parvovirus B19 NS1 protein 
mediates G2 arrest in the presence of an active Cdk1/cyclin B1 complex inducing 
activation of checkpoint pathways that can regulate cyclin B nuclear export (156, 157). 
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  An alternative strategy used by E4 protein of HPV16 is to prevent the nuclear entry of 
the Cdk1/cyclin B complex by sequestering the Cdk1/cyclin B kinase complex within the 
cytoplasm (158). Other viral proteins are suggested to induce G2/M arrest and inhibit 
the mitotic exit by interference with kinetochores, such as ICP0 protein of HSV-1 (159) 
or EC27 protein of the baculovirus that can act as a non-degradable Cdk1/cyclinB 
analog (160). EBV-EBNA3C inhibits the G2/M checkpoint (161), which may be realized 
via manipulation of Chk2 signaling (162). E1B-55K and E4orf3 genes of adenovirus type 
5 are sufficient to prevent mitotic arrest in the infected cell (163). However, one of the 
most studied viral G2 arrest is that induced by Vpr protein of HIV showing ability to 
manipulate key cellular pathways to ensure efficient replication. In the arrested cells the 
Cdk1/cyclin B1 complex remains inactive by binding of Vpr to chromatin or to specific 
splicing factors that activate ATR and promote the activity of the Wee1 kinase while 
inhibiting Cdc25 phosphatase (164–166). The results of this activation are changing the 
levels of Wee1 protein and downregulate the expression of genes in the MAPK pathway 
(167). 
By contrast, the AAV-induced G2 arrest is likely induced by the viral genome – a ssDNA 
molecule with terminal hairpin loops, prone to activate DNA damage responses, cell 
cycle arrest and/or, in cells lacking p53, apoptosis  (168).  
The cell cycle could play an important role also in the expression of HSV-1 late proteins 
by the activation of Cdk1 (169). In papillomaviruses (PV), an increased synthesis of 
capsid proteins in the G2 phase may involve mechanisms of transcription and 
translation during G2/M (170).  
Manipulation of cell cycle progression for more efficient viral replication is accomplished 
in the case of some viruses by creating a pseudo-S phase at the stage when the cellular 
DNA replication is complete. Thus, for the baculovirus both the viral EC27 protein and 
PCNA contribute to S phase entry following infection (160), whereas for HPV the 
involvement of the viral proteins E6 and E7 were demonstrated (171).  
Furthermore, the cell cycle phase can influence virion assembly and release as in the 
case of baculovirus. Specifically the viral EC27 protein is involved in the maturation of 
the viral particle and is required for the inter-insect transmission by the so-called 
occlusion-derived (ODV) viral form (172).  
Influenza A virus strains A/WSN/33 (H1N1), H3N2, H9N2 and PR8H1N1 can induce a 
cell cycle arrest in G0/G1 phase in infected cells associated to a decreased amount of 
hyperphosphorylated retinoblastoma (Rb) protein. DNA viruses such as SV40 (173, 
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  174), HPV (154) or adenovirus (175–177) can promote entry into S phase of the 
infected cells for an optimal synthesis of viral DNA. Other large DNA viruses like 
herpesviruses can promote G0/G1 phase arrest to avoid competition for cellular DNA 
replication resources (178).  
DDR pathways may also be involve in the viral G1/S arrest. Damage sensed via 
ATM/ATR pathways results in phosphorylation and activation of Chk2 and/or Chk1, two 
checkpoint kinases that can also phosphorylate downstream targets to initiate G1/S 
arrest (162, 179). Chk1/Chk2-mediated phosphorylation of p53 results in upregulation of 
p21, which functions as a Cdk2 inhibitor (180). In addition to upstream activators, Chk1 
and Chk2 are direct targets for viral inactivation of damage responses. HBV-HBx can 
have inhibitory effects on Chk1 activity while preventing ATR-mediated phosphorylation 
of Chk1 and intra-S phase checkpoint activation (181–183). 
The oncogenic viruses group can control G1/S transition via p53 inactivation to prevent 
apoptosis in infected cells. For example, HPV-E6 (184), KSHV-LANA (185), Ad-
E1B55K/E4orf6 (186) mediate the ubiquitination and proteasome-mediated degradation 
of p53 via recruitment of cellular factors. SV40-LTag association with p53 leads to p53 
inhibition (187). HBV-Hbx inhibits transcription from the p53 promoter, resulting in 
reduced p53 levels (188).  
Some viruses promote CDk2 activity via manipulation of its regulators. EBV-infected 
cells fail to accumulate p21 in response to DNA damaging agents even if p53 
expression and damage-induced phosphorylation remains unaffected (189). HBV, while 
activating ATR and downstream Chk1 phosphorylation, inhibits downstream signaling 
via degradation of p21, promoting viral replication (190). 
Understanding these complex interactions between viruses, cellular DNA damage and 
checkpoint responses can provide further tools for possible applications. For example, 
cellular repair proteins could represent potential targets for antiviral drugs. Another 
possibility is to use viruses as tools to study the role of cellular proteins in repair 
processes.  
Overall, the strategies used by viruses to manipulate the cell cycle are complex and 







Parvoviruses and the cell cycle 
 
Parvoviruses are able to block entry into the S phase using a mechanism of cell cycle 
regulation involving nuclear capsid assembly (191). The reaction of ssDNA convertion 
requires DNA polymerase delta, PCNA (192) as well as other S phase-induced factors. 
Interestingly, the S phase activation of the minute virus of mice (MVM) promoter P4, 
which directs the transcription unit encoding the NS proteins, is dependent on an E2F 
motif located in its proximal region (193).  
As the infection progresses, most parvoviruses destabilize the cell cycle eliciting a DDR 
as a strategy to support viral replication (179, 194, 195) and arresting cells at the S or 
G2/M phases. It is still unknown whether the cell cycle regulatory machinery or the S-
phase induced molecular interactions, could regulate parvovirus assembly and 
maturation. However, Riolobos et al (196) showed that the phosphorylation of Raf-1 
kinase of MAPK signaling pathway can play an important role in the nuclear entry of 
minute virus of mice (MVM) capsid assembly intermediates, being as well required for 
viral maturation. 
AAV2, a helpervirus dependent human parvovirus, exerts oncosuppressive activities on 
cells mainly by manipulating the cell cycle through a Rep78-dependend S-phase arrest 
(197). Furthermore, Rep78 can activate pRb and induce a S-phase arrest depending on 
a functional zinc finger motif within the C-terminus (197, 198). Interestingly, adenovirus 
E1A protein can rescue the Rep78-mediated cell cycle arrest during a productive 
infection. Importantly, Hermanns et al (199) reported a cell cycle arrest of AAV2 infected 
primary human fibroblasts particularly by lowering the levels of cell cycle regulatory 
proteins the cyclins A and B1, hypophosphorylated pRb and p107 and increasing levels 










	  3.3. RPA and DNA replication 
 
Replication protein A (RPA) was initially identified as an essential protein for SV40 DNA 
replication (200–202). RPA constitutes a heterotrimeric complex that is the main ss 
DNA binding protein (DBP) involved and equally required in many DNA processes such 
as repair, recombination, replication (203) or activation of cell cycle checkpoints (204) 
(shown in Figure 5). 
The main subunits are RPA1 (70 kDa), RPA2 (32 kDa), RPA3 (14 kDa). Additionally, 
Wold and colleagues (205) characterized a naturally occurring homologous form of the 
RPA2 subunit, named RPA4,  that can substitute for RPA2 in complex formation but 
cannot however support chromosomal DNA replication and cell proliferation. In another 
study of Wold et al (206) described an alternative RPA complex (aRPA) containing 
RPA1, RPA3 and RPA4 that, although it interacts with ssDNA in a similar fashion to the 
canonical RPA complex, it did not support DNA replication in vitro.  
The central elements of the biochemical composition of RPA are the six 
oligosaccharide/oligonucleotide binding folds (OB-folds) composed of five ß-strands 
arranged in a ß-barrel structure (207). RPA1 contains four OB-folds (DNA binding 
domain- A, DBD-B, DBD-C, and DBD-F), RPA2 and 3 contain only one each (DBD-D 
and DBD-E, respectively) (Figure 5A). DBD-F presents a lower affinity for ssDNA 
compared to DBD-A and DBD-B that constitute the major ssDNA binding affinity 
initiated at the 5’-side of ssDNA of 8-10 nucleotides (208). RPA3 is required for the 
stability of the heterotrimer (209). Importantly, RPA2 can interact with other proteins by 
its two domains, the N terminal phosphorylation and C-terminal alpha-helix domain 
(210). 
In the DNA repair process, RPA plays an important role in nucleotide excision repair 
interacting in the gap-filling reaction with RFC and PCNA (211), or with Rad51 and 
Rad52 in the homologous recombination repair of DSBs (212, 213). 
Moreover, RPA can interact and co-localize with the MRN complex. RPA is also 
involved in ATM signaling by stimulating ATM downstream activity to p53 and Chk2 
(214). 
During DNA replication, RPA participates in the initiation and elongation process by 
promoting the recruitment of DNA polymerases, in the switch of polymerase on the 
lagging strand as well as in coordinating the processing of Okazaki fragments (215).  
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  Although it was first described more than 30 years ago, the stress-dependent and –
independent phosphorylation of the RPA32 N-terminus still remains the most studied 
post-translational modification of the RPA complex (216). This process is demonstrated 
to be depended on the cell cycle (217) mainly at the G1/S phase transition being 
followed by a dephosphorylation phase after mitosis. At this stage, the activity of DNA-
PK, ATM and ATR appear to play an important role (218). ATR activation on RPA 
binding ssDNA activates cell cycle checkpoints, stabilizes stalled forks, supports DNA 
repair and the genome integrity (219). 
Vassin et al (220) found that RPA2 phosphorylation mutants which mimic the 
hyperphosphorylated form could not localize to DNA replication centers. The same 
study showed that RPA phosphorylation following DNA damage inhibited RPA from 
activating DNA replication and the recruitment of repair factors to sites of DNA damage.  
Knockdown studies showed the role of RPA on the cell cycle, DNA damage signaling 
and replication. Thus, RPA1 depleted cells appear to have a slower S phase 
progression followed by an G2/M arrest and formation of gamma-H2AX foci (221). 
Moreover, RPA1 depletion leads to phosphorylation of Chk2, ATM and activation of p21 
expression (222) but does not affect RPA2 or RPA3 levels in the cell (223). While some 
RPA1 mutants of ssDNA binding domains do not appear to affect RPA1 cellular 
functions, a deletion of DBD-C was unable to support DNA replication (223).  
 
RPA and viral DNA replication 
 
Although the two main RPA subunits RPA1 and RPA2 are known to be recruited to viral 
replication compartments of some DNA viruses, such as HSV-1, AdV, HPV, SV40, the 
exact role of each subunit in viral DNA replication is still unclear. Wilkinson and Weller 
(224) showed, by using a polymerase null virus, that the HSV-1 DNA synthesis did not 
induce RPA2 hyperphosphorylation and that endogenous hyperphosphorylated forms of 
RPA were not colocalized with the replication compartments of HSV-1.  
By knocking down RPA1 and other ATR pathway proteins such as ATRIP, CINP, 
Claspin, TopBP1 and HCLK2 it was shown that HSV-1 DNA replication significantly 
decreased (225). Loo and Melendy (226) reported that the interaction of RPA1 with the 
viral protein E1 of HPV was strongly inhibited by ssDNA, suggesting a  possible role in 
HPV DNA viral replication.   
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  However, most extensive studies on the involvement of specific RPA subunits in viral 
DNA replication used SV40 as a well-established model to study the molecular 
mechanisms involved in eukaryotic DNA replication (216, 227). Erdile and colleagues 
(228) expressed the 70-kDa human RPA subunit in E.coli and demonstrated that this 
subunit was unable to replace the RPA complex in SV40 DNA replication, suggesting 
that the other subunits are required for DNA replication. This conclusion was further 
supported by other results of the same group showing that monoclonal antibodies 
against the RPA2 subunit could inhibit the DNA replication (202). Furthermore, 
antiserum raised against purified recombinant RPA3 could inhibit the DNA replication to 
a certain extend indicating that this subunit may be involved in some steps of DNA 
replication (229). Importantly, the alternative RPA complex (aRPA) containing RPA1, 
RPA3 and RPA4 can interact with ssDNA and can inhibit the “canonical” RPA complex 
(RPA1, RPA2 and RPA3) from functioning in DNA replication due to two regions 
identified on RPA4 (206). By contrast, it was reported that a purified, recombinant 
subcomplex form composed of the 32- and 14-kDa subunits of RPA did not bind to the 
ss DNA, was unable to substitute the complete RPA complex and did not inhibit DNA 
replication, possibly by not interacting with proteins required for replication (201).  
Importantly, these studies indicate that the RPA2 and not the RPA1 subunit plays an 
essential role in the SV40 DNA replication (201, 228).  
Our present results support this concept of differential effects of the RPA subunits in 
viral DNA replication with RPA2 as the required gene for HSV-1 supported AAV2 DNA 
replication. 
Other studies on RPA implication in AAV DNA replication showed rather mixed results. 
In cells co-infected with AAV2 and either Ad or HSV-1, RPA2 was shown to be localized 
in the AAV RCs, even in absence of a viral ssDBP (230). The cellular RPA2 and the 
HSV-1 UL29 (ICP8) protein or the ss DNA binding protein (DBP) of adenovirus 
colocalize and interact with AAV Rep proteins and AAV DNA (57, 230, 231). 
Interestingly and in line with our results, Ni et al (12) showed that AAV DNA replication 
was significantly inhibited up to 90% upon treating the cells with monoclonal antibodies 
against either RPA2 or RFC and concluded that, together with PCNA and RFC, RPA2 is 
an essential component for AAV DNA replication. Of note, RPA2, PCNA and RFC were 
demonstrated to be required for SV40 DNA replication as well (200).  
Moreover, the addition of RPA2 or Ad-DBP to uninfected cell extracts enhanced AAV 
DNA replication (232), suggesting an important role of RPA2 in AAV DNA replication. 
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  Taken together, these results show the duality and the complex role of the two main 
RPA subunits in DNA replication and repair: RPA2, a well-known DNA damage marker, 
with implications mainly in viral DNA replication and RPA1, containing the main ssDNA-

























































Figure 5. A: Schematic representation of RPA1 (RPA70), RPA2 (RPA32) and RPA3 
(RPA14) protein DNA binding domains (DBD).  RPA70: DBD-A, DBD-B, DBD-C, and 
DBD-F.; RPA2: DBD-D; RPA3 (DBD-E). The N-terminal domain of RPA32 exists as an 
extended unstructured domain and contains most of the phosphorylation sites for the 
trimer. B: RPA protein as required for all four major DNA metabolism pathways and 
proteins involved as listed.  
Figure adapted from: Zou Y, Liu Y, Wu X, Shell SM, 2006, Functions of Human 
Replication Protein A (RPA): From DNA Replication to DNA Damage and Stress 





	  4. Specific aims of PhD thesis 
 
 
The first aim of this thesis was to establish an assay that allowed visualizing and 
investigating AAV2 gene expression/DNA replication and cell cycle progression by live 
cell microscopy. This work was recently published in the Journal of Virology (doi 
10.1128/JVI.00357-17). 
In this study, our specific question was how AAV2 and HSV-1 can co-exist in a cell 
population. We showed that in co-infected cultures, AAV2 DNA replication takes place 
almost exclusively in S/G2 cells, while HSV-1 DNA replication is restricted to G1. We 
observed that AAV2 rep gene expression is cell cycle dependent, and gives rise to 
distinct time controlled windows for HSV-1 replication. High Rep protein levels in S/G2 
phases support AAV2 replication and inhibit HSV-1 replication. Conversely, low Rep 
protein levels in G1 permit HSV-1 replication, but are insufficient for AAV2 replication. 
Live microscopy revealed that not only wtAAV2 replication but also reporter gene 
expression from both single-stranded and double-stranded (self-complementary) 
recombinant AAV2 vectors preferentially occurs in S/G2 cells, suggesting that the S/G2 
preference is independent of the nature of the viral genome. Interestingly, however, a 
substantial proportion of the S/G2 cells transduced by the double-stranded but not the 
single-stranded recombinant AAV2 vectors progressed through mitosis in absence of 
the helper virus. We concluded that cell cycle-dependent AAV2 rep expression 
facilitates cell cycle-dependent AAV2 DNA replication, and inhibits HSV-1 DNA 
replication. This may limit competition for cellular and viral helper factors, and hence, 
creates a biological niche for both viruses to productively replicate in distinct sets of 
dividing cells. 
The second aim was to investigate the effect of cellular proteins that are known to 
interact with AAV2 DNA either directly or via the AAV2 Rep proteins on the transduction 
efficiencies of single-stranded and double-stranded AAV2 vectors.  
Thus, we performed an image-based RNAi screen to investigate the effects of a 
functional group of cellular proteins known to interact with AAV2 DNA directly or via the 
AAV2 Rep proteins in AAV2 replication compartments, on the transduction efficiencies 
of ss and ds AAV vectors on a single cell level. We identified cellular proteins that 
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  positively or negatively affected the transduction efficiency of both ss and ds AAV2 
vectors as well as proteins that presented differential effects on the two different vector 
types. In particular, the posttranscriptional knockdown of the single-stranded DNA 
binding protein RPA1 resulted in the most differential transduction efficiencies of ss and 
ds AAV vectors of all proteins tested, and these effects were reversed when the 
knockdown of endogenous RPA1 was complemented with exogenous RPA1 in our 
validation assay. The RPA2 subunit of the RPA heterotrimer had a similar effect as 
RPA1 on the transduction efficiencies of the two vector types. Interestingly however, 
RPA2 appeared to enhance HSV-1 supported AAV2 replication while RPA1 had no 
significant positive or negative effect on virus replication. In conclusion, this RNAi-based 
study provides novel insights into the roles of host factors, such as the subunits of the 























	  5. Results 
 
       
5.1. Cell cycle-dependent expression of AAV2 Rep in HSV-1 co-infections gives 
rise to a mosaic of cells replicating either AAV2 or HSV-1 
 
Francesca D. Franzoso, Michael Seyffert, Rebecca Vogel, Artur Yakimovich, Bruna de 
Andrade Pereira, Anita F. Meier, Sereina O. Sutter, Kurt Tobler, Bernd Vogt, Urs F. 
Greber, Hildegard Büning, Mathias Ackermann, and Cornel Fraefel     
 
 





I have established a live cell fluorescence microscopy assay to assess the cell cycle 
phase-dependent gene expression and replication of AAV2. This work is shown here as 
part of the manuscript that was recently published in Journal of Virology. 
 
Designed and performed live imaging experiments (Figures 5 and 7; Tables 2 and 3; 
Supplementary files 1, 2, 3, 4) 
Designed and performed qPCR experiments (Figure 3) 
Minor contribution to the fluorescence in situ hybridization (FISH) assay development 
(Figures 2 and 4) 









Cell Cycle-Dependent Expression of
Adeno-Associated Virus 2 (AAV2) Rep in
Coinfections with Herpes Simplex Virus
1 (HSV-1) Gives Rise to a Mosaic of Cells
Replicating either AAV2 or HSV-1
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ABSTRACT Adeno-associated virus 2 (AAV2) depends on the simultaneous presence
of a helper virus such as herpes simplex virus 1 (HSV-1) for productive replication. At
the same time, AAV2 efﬁciently blocks the replication of HSV-1, which would even-
tually limit its own replication by diminishing the helper virus reservoir. This dis-
crepancy begs the question of how AAV2 and HSV-1 can coexist in a cell popula-
tion. Here we show that in coinfected cultures, AAV2 DNA replication takes place
almost exclusively in S/G2-phase cells, while HSV-1 DNA replication is restricted
to G1 phase. Live microscopy revealed that not only wild-type AAV2 (wtAAV2)
replication but also reporter gene expression from both single-stranded and
double-stranded (self-complementary) recombinant AAV2 vectors preferentially
occurs in S/G2-phase cells, suggesting that the preference for S/G2 phase is inde-
pendent of the nature of the viral genome. Interestingly, however, a substantial pro-
portion of S/G2-phase cells transduced by the double-stranded but not the single-
stranded recombinant AAV2 vectors progressed through mitosis in the absence of
the helper virus. We conclude that cell cycle-dependent AAV2 rep expression facili-
tates cell cycle-dependent AAV2 DNA replication and inhibits HSV-1 DNA replication.
This may limit competition for cellular and viral helper factors and, hence, creates a
biological niche for either virus to replicate.
IMPORTANCE Adeno-associated virus 2 (AAV2) differs from most other viruses, as it
requires not only a host cell for replication but also a helper virus such as an adeno-
virus or a herpesvirus. This situation inevitably leads to competition for cellular re-
sources. AAV2 has been shown to efﬁciently inhibit the replication of helper viruses.
Here we present a new facet of the interaction between AAV2 and one of its helper
viruses, herpes simplex virus 1 (HSV-1). We observed that AAV2 rep gene expression
is cell cycle dependent and gives rise to distinct time-controlled windows for HSV-1
replication. High Rep protein levels in S/G2 phase support AAV2 replication and in-
hibit HSV-1 replication. Conversely, low Rep protein levels in G1 phase permit HSV-1
replication but are insufﬁcient for AAV2 replication. This allows both viruses to pro-
ductively replicate in distinct sets of dividing cells.
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Viruses depend on host cell factors for the replication of their genome. As thenucleic acid metabolites accumulate during the S phase of the cell cycle, many
DNA viruses, such as autonomous parvoviruses, adenoviruses, or herpesviruses, have
evolved mechanisms to manipulate cell cycle progression and induce S- or G2-phase
arrest, which allows them to replicate their genomes in concert with cellular DNA (1–3).
Herpes simplex virus 1 (HSV-1) is an enveloped human pathogen with a double-
stranded DNA genome of 152 kbp encoding approximately 90 proteins (reviewed in
reference 4). Among these proteins are 7 enzymes, which are essential and sufﬁcient to
support HSV-1 DNA replication in cells, and several accessory proteins, including uracil
DNA glycosylase, alkaline exonuclease, thymidine kinase, or ribonucleotide reductase,
which are homologous to important cellular S-phase proteins. HSV-1 may therefore be
less dependent on cellular proteins and a speciﬁc phase of the cell cycle. Indeed, unlike
many other DNA viruses, HSV-1 has been shown to replicate well outside the S phase
and to possess mechanisms for actively arresting cells in G1 and G2 phases (5–9).
In contrast, adeno-associated virus 2 (AAV2) is a nonpathogenic human parvovirus
with a small, single-stranded DNA genome of 4,680 nucleotides. As for herpesviruses,
the AAV2 genome is packed in an icosahedral capsid; however, it lacks a lipid envelope
and is smaller than the herpesvirus capsid. The AAV2 genome contains only two
clusters of genes, rep and cap, ﬂanked by inverted terminal repeats (ITRs), which contain
the viral origin of DNA replication and a packaging signal. cap gene expression is
controlled by the p40 promoter and gives rise to the capsid proteins VP1, VP2, and VP3,
which, due to alternative start codons, differ in their N termini (reviewed in reference
10). In addition, a nested open reading frame within the cap gene encodes a protein
designated assembly-activating protein, which is believed to be required for AAV2
capsid assembly in the nucleolus (11). The rep gene cluster encodes four Rep isoforms,
Rep40, Rep52, Rep68, and Rep78, due to transcription from two different promoters, p5
and p19, and alternative splicing at an intron near the C terminus. The multifunctional
Rep proteins are involved in diverse processes of the AAV2 life cycle, including DNA
replication, the regulation of gene expression, genome packaging, and site-speciﬁc
integration (12–17). The functions of the Rep proteins include site-speciﬁc DNA-binding
and endonuclease activities (Rep68 and -78) as well as site-nonspeciﬁc ATPase/helicase
activity (all Rep isoforms) (18–22). Likely because of its low genetic complexity, AAV2
depends not only on a cell for productive replication but also on the presence of a
helper virus, such as HSV-1, adenovirus 2 (AdV2), or human papillomavirus 16 (HPV16)
(23–25). In the absence of a helper virus, AAV2 enters cells and establishes latent
infection by maintaining its DNA episomally or inserting it into the host cell genome,
preferentially at a site termed AAVS1 on human chromosome 19 (14, 26–28). The
dependence of AAV2 on a helper virus inevitably leads to competition for cellular
resources and viral factors that are essential for both AAV2 and helper virus replication,
such as the HSV-1 ICP8 protein and the helicase/primase complex (29–31). HSV-1 also
provides accessory proteins, including the ICP0 protein and the viral DNA polymerase
(31), and may condition the cellular environment to promote AAV2 replication, e.g., by
interfering with cellular DNA damage signaling (32) or cell cycle progression (5–9, 33).
AAV2 has been demonstrated to efﬁciently inhibit the replication of its helper
viruses human adenovirus 2 of species C (HAdV-C2) (34–36) and HSV-1 (37, 38). For
example, the Rep-mediated inhibition of the protein kinases protein kinase A (PKA) and
cAMP-dependent protein kinase catalytic subunit (PRKX), both members of the cyclic
AMP (cAMP) signal transduction pathway, results in the decreased expression of
cAMP-responsive genes and contributes to the Rep-mediated inhibition of AdV repli-
cation (39–42). Although the mechanism of how AAV2 inhibits HSV-1 replication is less
well understood, it also involves the large Rep proteins, in particular the DNA-binding
and ATPase/helicase activities of Rep68 and -78 (43). We have previously shown that
Rep68 can bind to consensus Rep-binding sites located on the HSV-1 genome and that
the Rep helicase domain is sufﬁcient to inhibit DNA replication if binding is facilitated
(44). Interestingly, however, while the formation of mature HSV-1 replication compart-
ments (RCs) is almost entirely prevented in cells that support productive AAV2 repli-
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cation (38), the yield of HSV-1 progeny from coinfected cultures is only approximately
10-fold lower than that in cultures infected with HSV-1 alone (our unpublished obser-
vations). Because of this observation and the fact that HSV-1 can replicate well in
different phases of the cell cycle, we addressed the following two questions: (i) do
HSV-1-provided helper functions allow AAV2 to replicate in different phases of the cell
cycle, and (ii) do AAV2 and HSV-1 replicate in different sets of cells in coinfected
cultures?
The results presented here imply that HSV-1 does not extend its ability to replicate
in different phases of the cell cycle to AAV2. In fact, AAV2 gene expression in both the
presence and absence of the helper virus and AAV2 replication occur almost exclusively
in S/G2-phase cells. HSV-1 lost its ability to replicate in S/G2-phase cells in the presence
of AAV2 rep gene expression/DNA replication but still replicated in G1 phase.
RESULTS
For productive infection, AAV2 requires a helper virus and a cell in S/G2 phase.
We examined the formation of AAV2 RCs in HeLa Fucci cells, which express ﬂuorescent
ubiquitination-based cell cycle indicators (Fucci) (45). Speciﬁcally, HeLa Fucci cells
express green and red ﬂuorescent proteins fused to geminin and Cdt1, respectively. In
the G1 phase of the cell cycle, geminin undergoes proteasome-dependent degrada-
tion, and the cells appear red. In the S, G2, and M phases of the cell cycle, Cdt1 is
ubiquitinated and degraded; thus, the cells appear green. Cells in early S phase
simultaneously express Cdt1 and geminin and appear orange. In early G1 phase, no
ﬂuorescence marker is expressed.
In the ﬁrst set of experiments, HeLa Fucci cells were infected with wild-type HSV-1
(wtHSV-1) alone or coinfected with wtAAV2 and wtHSV-1. After 24 h, viral RCs were
visualized by confocal laser scanning microscopy (CLSM) with antibodies speciﬁc for the
HSV-1 and AAV2 DNA-binding proteins ICP8 and Rep, respectively. In cells infected with
HSV-1 alone, we detected HSV-1 RCs in both red ﬂuorescent (G1-phase) and green
ﬂuorescent (S/G2-phase) cells (S/G2-to-G1-phase ratio, 1.11  0.36) (Fig. 1A and C),
which is consistent with data from previous studies showing that HSV-1 can replicate
in G1, S, and G2 phases (5–9). In contrast, AAV2 RCs were identiﬁed predominantly in the
nuclei of cells expressing the green ﬂuorescent S/G2-phase marker geminin (Fig. 1B and
C) (S/G2-to-G1-phase ratio, 6.65  1.01). The S/G2-to-G1-phase ratios of total mock-
infected HeLa Fucci cells (not gated for RCs) were 1.75  0.10 at 0 h postinfection (p.i.)
and 1.20  0.05 at 24 h p.i.; the S/G2-to-G1-phase ratios were 1.04  0.02 for total
wtHSV-1-infected and 0.93  0.02 for wtAAV2- and wtHSV-1-coinfected HeLa Fucci
cells. The preference of AAV2 for replication in the S/G2 phase of the cell cycle was also
conﬁrmed by ﬂuorescence in situ hybridization (FISH) with a probe speciﬁc for AAV2
DNA (Fig. 2A). While no FISH signal was detected in noninfected cells (Fig. 2A, top), in
the cultures infected with wtAAV2 alone, ﬂuorescent dots representing AAV2 genomes
were observed in both S/G2- as well as G1-phase cells (Fig. 2A, middle). Coinfection with
the helper virus supported the formation of AAV2 RCs, and these RCs were found
predominantly in the nuclei of S/G2-phase cells (Fig. 2A, bottom, and B). Of note, the
AAV2 genomes that were observed in the absence of the helper virus (Fig. 2A, middle)
were not visible in Fig. 2A (bottom) because the laser intensity was strongly reduced for
the acquisition of the brightly ﬂuorescent AAV2 RCs. Taken together, these data show
that efﬁcient AAV2 replication requires not only the presence of a helper virus but also
that the cell be in the S/G2 phase of the cell cycle. Therefore, HSV-1 cannot extend its
ability to replicate in different phases of the cell cycle to AAV2.
In coinfected cultures, HSV-1 DNA replication is inhibited speciﬁcally in S/G2-
phase cells. In the above-described experiments, we monitored cell cycle phases and
virus replication in nongated cells (Fig. 1A and B and 2A), and we also determined cell
cycle phases of cells “gated” for viral replication markers (Fig. 1C and 2B). Next, we
analyzed virus replication in cells gated for the cell cycle phase. Speciﬁcally, HeLa Fucci
cells were infected with wtHSV-1 or coinfected with wtHSV-1 and wtAAV2. After 24 h,
cells positive for Cdt1 (G1 phase) (red) or geminin (S/G2 phase) (green) were sorted by
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ﬂuorescence-activated cell sorter (FACS) analysis, and equal cell equivalents were
analyzed by Southern blotting, Western blotting (WB), and quantitative PCR (qPCR).
Consistent with the ﬁndings described above, the results of these assays showed that
in the absence of AAV2, HSV-1 DNA replication was at least as efﬁcient in S/G2 phase
as it was in G1 phase (Fig. 3A and C), while AAV2 DNA replication in S/G2 phase was at
least 6-fold more efﬁcient than in G1 phase (Fig. 3A and D). HSV-1 replication in
G1-phase cells appeared to be equally efﬁcient in the presence and absence of AAV2
(Fig. 3A and C). Interestingly, however, in the presence of AAV2, HSV-1 DNA was no
longer detected by Southern blotting in S/G2-phase cells (Fig. 3A), and qPCR revealed
an approximately 4-fold reduction of HSV-1 DNA levels in S/G2-phase cells compared to
those in G1-phase cells from coinfected cultures and an approximately 6-fold reduction
compared to those in S/G2-phase cells from cultures infected with HSV-1 alone (Fig. 3C).
As an infection control, the HSV-1 ICP0 and AAV2 Rep proteins were detected by
Western blotting (Fig. 3B). Of note, the levels of AAV2 DNA appear to directly correlate
with the levels of AAV2 Rep proteins in the different cell cycle phases (Fig. 3A and B).
Cell cycle phases of HeLa Fucci cells sorted into G1 (Cdt1) (red), early S (Cdt1 and
geminin) (orange), and S/G2 (geminin) (green) populations by FACS analysis were
conﬁrmed by 4=,6-diamidino-2-phenylindole (DAPI) staining and ﬂow cytometry (not
shown).
These data show that the previously reported AAV2-mediated inhibition of HSV-1
replication (37, 38) is speciﬁc to the S/G2 phase of the cell cycle and correlates with
FIG 1 Codetection of cell cycle phases and viral replication compartments. (A and B) HeLa Fucci cells
were infected with wtHSV-1 (MOI of 3) or coinfected with wtAAV2 (MOI of 4,000) and wtHSV-1 (MOI of
3). After 24 h, the cells were ﬁxed and processed for immunoﬂuorescence analysis and CLSM. (A) HSV-1
RCs were visualized with a primary antibody speciﬁc for the HSV-1 major DNA-binding protein ICP8 and
an AF-405-labeled secondary antibody (blue). (B) AAV2 RCs were visualized with a primary antibody
speciﬁc for the AAV2 Rep proteins and an AF-405-labled secondary antibody (blue). Bars  10 m.
Arrowheads in panels A and B indicate cells positive for HSV-1 or AAV2 RCs and either the red ﬂuorescent
G1-phase marker Cdt1 (I) or the green ﬂuorescent S/G2-phase marker geminin (II). (C) From the cultures
shown in panels A and B, approximately 30 cells containing HSV-1 or AAV2 RCs (blue) were analyzed for
their cell cycle phase (G1, early S, and S/G2). The graphs show mean values from six independent
experiments; error bars indicate standard deviations of the means.
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efﬁcient AAV2 replication in these cell cycle phases. The next experiment was per-
formed to investigate whether HSV-1 can replicate in G1-phase cells despite the
presence of AAV2 genomes or simply because AAV2 genomes are absent from these
cells. For this, HeLa Fucci cells were coinfected with wtAAV2 and recombinant HSV-1
that encodes enhanced cyan ﬂuorescent protein (ECFP) fused with the HSV-1 ICP4
protein (rHSV-1vECFP-ICP4), thus facilitating the observation of HSV-1 RCs due to the
binding of the ﬂuorescent ICP4 fusion protein to the replicating HSV-1 DNA in the cell
nucleus (46). After 24 h, the cells were ﬁxed, and FISH staining was performed by using
an Alexa Fluor 647 (AF-647)-labeled AAV2 DNA probe. The micrographs shown in Fig.
4 demonstrate that HSV-1 RCs are formed in G1-phase cells despite the presence of
AAV2 genomes.
FIG 2 Codetection of cell cycle phases and AAV2 genomes. HeLa Fucci cells were mock infected, infected with wtAAV2 alone (MOI of
4,000), or coinfected with wtAAV2 (MOI of 4,000) and wtHSV-1 (MOI of 3). After 24 h, the cells were ﬁxed and processed for ﬂuorescence
in situ hybridization (FISH) and CLSM. (A) AAV2 DNA (yellow) was detected with an AF-647-labeled probe as described in Materials and
Methods. The red and green signals indicate cells in G1 (Cdt1) and S/G2 (geminin) phases, respectively. The orange cells observed in some
cultures are in early S phase, where they express both Cdt1 and geminin. Areas in the box were enlarged (right column). Bars  10 m.
(B) From the wtAAV2- and wtHSV-1-coinfected cultures shown in panel A, approximately 30 cells containing AAV2 RCs were analyzed for
their cell cycle phase (G1, early S, and S/G2). The graph shows mean values from six independent experiments; error bars indicate standard
deviations of the means.
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Cell cycle-dependent AAV2 DNA replication is controlled by cell cycle-
dependent AAV2 rep expression. In the absence of a helper virus, gene expression
from replication-defective recombinant AAV2 vectors was previously shown to occur
preferentially in the S phase of the cell cycle (47, 48). To address the question of
whether this also applies when a helper virus is present, we coinfected HeLa Fucci cells
with wtHSV-1 and recombinant AAV2 vectors encoding ﬂuorescent reporter proteins
fused in frame with AAV2 Rep (rAAVCFPRep and rAAVYFPRep). The AAV2 p5 promoter
used in these vectors for the transcriptional control of reporter gene expression is
highly regulated during coinfection; in particular, its activity is very low in the absence
of HSV-1. Therefore, we also used a recombinant AAV2 vector that expresses a reporter
gene from the constitutively active human cytomegalovirus (CMV) IE1 enhancer/
promoter (rAAVCFPNeo) to exclude a potential promoter effect responsible for the
observed cell cycle-dependent AAV2 DNA replication/gene expression. Viral gene
expression and the cell cycle phase were determined by ﬂuorescence microscopy or
ﬂow cytometry. Upon coinfection of HeLa Fucci cells with rAAVCFPNeo and wtHSV-1,
the majority of the cyan ﬂuorescent cells was indeed in S/G2 phase, approximately 10%
of the cells were in G1 phase, and 10% were in early S phase (Fig. 5A and B). A similar
distribution was observed upon coinfection of HeLa Fucci cells with rAAVCFPRep and
wtHSV-1: approximately 81% of the AAV2-transduced (ECFP-positive) cells were in S/G2
phase, while only 19% were in G1 phase, as determined by ﬂow cytometry (Table 1). The
inefﬁcient AAV2 gene expression in G1 phase was also observed in other cell lines,
including AT22, HCT116, and normal human ﬁbroblast (NHF) cells (Table 1). For
FIG 3 Viral DNA replication in different phases of the cell cycle. HeLa Fucci cells were mock infected, infected with either
wtAAV2 (MOI of 8,000) or wtHSV-1 (MOI of 3), or coinfected with wtAAV2 (MOI of 8,000) and wtHSV-1 (MOI of 3). After 24
h, cells positive for Cdt1 (G1 phase) (red) or geminin (S/G2 phase) (green) were sorted by FACS analysis and subjected to
Southern and Western blot analyses. (A) Southern blot analysis for detection of HSV-1 and AAV2 DNA (equal cell
equivalents were loaded into the different lanes) (ss, single stranded; rfm, replication-form monomer; rfd, replication-form
dimer). (B to D) Western blot analysis to control for virus infection (HSV-1 ICP0 and AAV2 Rep; actin was used as a loading
control) (B) and qPCR to quantify viral DNA (C and D). Graphs in panels C and D show mean values for relative HSV-1 or
AAV2 DNA quantities from triplicate experiments; error bars indicate standard deviations of the means.
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example, in AT22 ﬁbroblast cultures coinfected with rAAVYFPRep and wtHSV-1, more
than 80% of AAV2-transduced (enhanced yellow ﬂuorescent protein [EYFP]-positive)
cells were in S or G2 phase, while only approximately 16% of these cells were in G1
phase (Table 1), although the majority (approximately 60%) of the nongated cells in the
culture was in G1 phase (not shown). Therefore, HSV-1 helper functions appear to
support neither AAV2 replication nor AAV2 (rep) gene expression in G1 cells, indepen-
dent of the promoter, p5 or CMV. Inefﬁcient AAV2 gene expression in G1 phase and,
consequently, low levels of AAV2 Rep proteins (as indeed shown in Fig. 3B) are likely
responsible for the inefﬁcient AAV2 replication and the inefﬁcient inhibition of HSV-1
replication in this cell cycle phase, as AAV2 Rep proteins are known to be essential for
AAV2 replication and also responsible for the inhibition of HSV-1 replication (43, 49).
Next, we addressed the question of whether, in coinfected cultures, HSV-1 replica-
tion is allowed in G1-phase cells and inhibited in S/G2-phase cells, because AAV2 rep is
expressed efﬁciently only in S/G2-phase but not in G1-phase cells. For this, we used
recombinant HSV-1 that encodes the VP16 protein fused with EYFP (rHSV48EYFP) (50).
EYFP-VP16 accumulates on HSV-1 DNA and hence is a marker for HSV-1 RCs (50, 51). To
FIG 4 Codetection of AAV2 genomes, HSV-1 RCs, and cell cycle phases. HeLa Fucci cells were coinfected with wtAAV2 (MOI of 4,000) and
rHSV-1vECFP-ICP4 (MOI of 3). After 24 h, the cells were ﬁxed and processed for FISH and CLSM. (A) AAV2 DNA (yellow) was detected with
an AF-647-labeled probe as described in Materials and Methods. HSV-1 RCs were detected by the binding of the HSV-1 ECFP-ICP4 fusion
protein to HSV-1 DNA (blue). The red and green signals indicate cells in G1 (Cdt1) and S/G2 (geminin) phases, respectively. The area in the
box (top row, merge) is enlarged in the second row and in panel B. Bars 20 m. (B) Enlargement and sectioning of the HSV-1 RC-positive
cell shown in panel A (box in the top row) reveal the subcellular localization of AAV2 genomes (red arrows). For clarity, the red and green
channels were omitted.
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simultaneously visualize AAV2 Rep, we used rAAVCFPRep, which encodes an ECFP-Rep
fusion protein from the viral p5 promoter and allows not only cell cycle-dependent
replication of the viral genome in the presence of a helper virus but also monitoring
of AAV2 RCs via interactions of the ﬂuorescent Rep fusion protein with replicating
viral DNA (31) (see Movie S1 in the supplemental material). As expected, in cultures
coinfected with rHSV48EYFP and rAAVCFPRep, HSV-1 RCs and AAV2 RCs were not
codetected in individual cells (Fig. 5C, left). However, in cells coinfected with
rHSV48EYFP and rAAVCFPNeo, which encodes ECFP but no AAV2 Rep proteins, yellow
ﬂuorescent HSV-1 RCs were readily detected in both ECFP-positive and ECFP-negative cells
FIG 5 Cell cycle-dependent AAV2 gene expression controls the replication of both AAV2 and HSV-1 in coinfected cultures. (A) HeLa
Fucci cells were coinfected with rAAVCFPNeo (MOI of 4,000) and wtHSV-1 (MOI of 3). Images were acquired by automated
epiﬂuorescence microscopy using ImageXpress Micro XL (Molecular Devices) and ﬂuorescence ﬁlters (Semrock) for ECFP (AAV2 gene
expression) (blue), EGFP (S/G2 phase) (green), and TRITC (G1 phase) (red). Bars  20 m. (B) HeLa Fucci cells were coinfected with
rAAVCFPNeo (MOI of 1,000) and wtHSV-1 (MOI of 3), and 20 h later, the cell cycle phase (G1, early S, and S/G2) of rAAVCFPNeo-
transduced cells was determined by the expression of Ctd1 (red) and geminin (green). A total of 40,000 cells (events) per sample were
counted by ﬂow cytometry. The graph shows mean values from triplicate experiments; error bars indicate standard deviations of the
means. (C) HeLa cells were coinfected with rHSV48EYFP (MOI of 3) and either rAAVCFPRep (MOI of 4,000) or rAAVCFPNeo (MOI of
4,000). After 24 h, cells were examined by using a standard ﬂuorescence microscope. Bars  10 m. (D) From the cultures shown in
panel C, 50 cells containing yellow ﬂuorescent HSV-1 RCs were analyzed for the presence of AAV2 RCs in rHSV48EYFP- and
rAAVCFPRep-coinfected cultures or ECFP ﬂuorescence in rHSV48EYFP- and rAAVCFPNeo-coinfected cultures. The graph shows mean
values from triplicate experiments; error bars indicate standard deviations of the means.
TABLE 1 Cell cycle phases of AAV2-transduced cells
Cell line Infectiond
% of cells in phase
G1 S S/G2 G2
HeLa Fuccia rAAVCFPRep 19 81
AT22b rAAVYFPRep 16 40 44
HCT116c rAAVYFPRep 20 33 47
NHFb rAAVCFPRep 17 35 48
aCell cycle phases were determined by ﬂow cytometry with ﬂuorescent ubiquitination-based cell cycle
indicators (Fucci).
bCell cycle phases were determined by ﬂow cytometry with propidium iodide.
cCell cycle phases were determined by ﬂow cytometry with DAPI.
dCoinfected with HSV-1.
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(Fig. 5C, right). By using an epiﬂuorescence microscope, cells positive for yellow ﬂuorescent
HSV-1 RCs were examined for ECFP ﬂuorescence (Fig. 5D). In the rHSV48EYFP- and
rAAVCFPRep-coinfected cultures, less than 5% of the cells containing HSV-1 RCs were
ECFP-Rep positive. In contrast, in rHSV48EYFP- and rAAVCFPNeo-coinfected cultures, ap-
proximately 50% of the cells containing HSV-1 RCs were also positive for the AAV2 marker
ECFP. Since rAAVCFPNeo transduction was observed predominantly in the S/G2 phase of
the cell cycle (Fig. 5A and B), these data suggest that AAV2 infection or nonreplicating AAV2
DNA per se is not sufﬁcient to inhibit HSV-1 replication in S/G2 phase but that rep expression
is required. This is also supported by a previous ﬁnding that UV-inactivated wtAAV2
genomes, which do not express any AAV2 genes, did not inhibit HSV-1 replication (43). In
conclusion, cell cycle-dependent AAV2 rep expression seems to be responsible for the
observed negative correlation between HSV-1 and AAV2 replication efﬁciencies in different
phases of the cell cycle. Low Rep levels in G1 phase allow HSV-1 but not AAV2 to replicate,
while high Rep levels in S/G2 phase support AAV2 replication and block HSV-1 replication.
Both single-stranded and double-stranded AAV2 vectors predominantly trans-
duce cells in S/G2 phase, independent of the presence or absence of a helper
virus. We used two different approaches to test whether the single-stranded nature of
AAV2 DNA plays a role in cell cycle-dependent AAV2 gene expression: transfection of
plasmid-cloned AAV2 genomes and infection with self-complementary recombinant
AAV2 (scAAV2) vectors, which can form double-stranded DNA by self-annealing and
therefore do not depend on second-strand synthesis for viral gene expression. Specif-
ically, HeLa Fucci cells were transfected with plasmids containing rep-positive (pAAVCF-
PRep) or rep-negative (pAAVCFPp5) recombinant AAV2 genomes and 4 h later were
mock infected or infected with wtHSV-1. After 24 h, the cells were examined by CLSM.
The results are shown in Fig. 6 and are summarized as follows: ECFP ﬂuorescent AAV2
RCs were readily detected in both G1- and in S/G2-phase cells of cultures transfected
with pAAVCFPRep and infected with the helper virus (Fig. 6A). In the presence of HSV-1,
ECFP ﬂuorescence was also detected both in G1- and in S/G2-phase cells of cultures
transfected with pAAVCFPp5, but in these cells, ECFP ﬂuorescence was diffuse, and
AAV2 RCs were not observed because of the absence of rep (Fig. 6B). No ECFP
ﬂuorescence was observed in the absence of HSV-1, as both plasmids use the helper
virus-dependent AAV2 p5 promoter for transgene expression (not shown).
To conﬁrm that HSV-1-supported AAV2 DNA replication can indeed take place in G1
phase when the template is a circular double-stranded DNA, HeLa Fucci cells were
transfected with pAAVCFPRep and 4 h later were mock infected or infected with
wtHSV-1. After 24 h, episomal DNA was prepared from G1- and S/G2-phase cells
according to methods described previously by Hirt (52) and subjected to qPCR with
primers speciﬁc for rep. The graph in Fig. 6C shows that the relative AAV2 DNA content
in G1-phase cells is 80% larger in the presence of the helper virus, presumably because
of DNA replication. We then tested whether HSV-1 DNA replication was also blocked in
G1-phase cells when rep is expressed from a plasmid-cloned recombinant AAV2 ge-
nome. The graph in Fig. 6D shows that this is clearly the case. The HSV-1 DNA content
of ECFP (AAV2)- and Cdt1 (G1-phase) (red)-double-positive HeLa Fucci cells transfected
with pAAVCFPRep prior to HSV-1 infection was reduced by more than 60% compared
to that in cells transfected with rep-negative pAAVCFPp5 plasmid DNA prior to infection
with the helper virus. In summary, these data show that AAV2 (rep) gene expression,
AAV2 genome replication, and the inhibition of HSV-1 replication can take place in
G1-phase cells when the AAV2 genome is provided as a circular double-stranded rather
than a linear single-stranded DNA template.
These data suggest that AAV2 single-strand synthesis may be the limiting factor for
efﬁcient AAV2 gene expression/genome replication in G1 phase, and accordingly, one
would expect that scAAV2 vectors would support gene expression in this cell cycle
phase. To investigate this possibility, we infected HeLa Fucci cells with scAAVCFP in
presence or absence of the helper virus and monitored reporter gene expression (ECFP)
and the cell cycle phase from 2 to 20 h after infection (Fig. 7). Indeed, 20 h after
infection, many transgene-positive G1-phase cells (purple) were observed in scAAVCFP-
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FIG 6 Detection of cell cycle phases, AAV2 gene expression, and virus replication in cells transfected with circular, double-stranded rep-positive
or rep-negative recombinant AAV2 genomes. (A and B) HeLa Fucci cells were transfected with pAAVCFPRep (A) or pAAVCFPp5 (B) and infected
with wtHSV-1 (MOI of 2) 4 h later. After 24 h, cells were examined by CLSM with ﬁlters speciﬁc for Cdt1 (G1 phase) (red), geminin (S/G2 phase)
(green), and ECFP (AAV2) (blue). The framed areas in panels A and B are shown at a higher magniﬁcation on the right. Arrowheads in panel A
(Continued on next page)
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infected cultures in the absence of the helper virus (Fig. 7A, left). However, tracking of
individual cells over time revealed that the transgene-positive G1-phase cells observed
20 h after infection originated from cells that became transgene positive in S/G2 phase
and then went through mitosis (Fig. 7A, right, arrows; see also Movie S2 in the
supplemental material). Occasionally, cells turned transgene positive in G1 phase (not
shown). Coinfection with wtHSV-1 largely prevented the generation of transgene-
positive G1 cells (Fig. 7A), presumably because of HSV-1-mediated G2 arrest (5, 33). As
expected from the above-described data, the vast majority of the cells infected with the
single-stranded AAV2 vector (rAAVCFPNeo) turned transgene positive in S/G2 phase
and did not progress through mitosis, independent of the presence or absence of the
helper virus (Fig. 7A and Movie S3). Also as expected from the above-described data,
transgene-positive G1-phase cells were also occasionally observed in rAAVCFPNeo-
infected cultures in the absence of the helper virus. These cells often but not always
originated from transgene-positive S/G2-phase cells that progressed to G1 phase,
sometimes without division (Fig. 7A). To quantify the observations from live micros-
copy, we tracked and counted cells over time from the moment when AAV2 vector-
encoded ECFP ﬂuorescence became visible. The graph in Fig. 7B shows that more than
90% of the cells turned ECFP positive in S/G2 phase, independent of the genome
structure, whether single stranded or double stranded (self-complementary), or the
presence or absence of the helper virus. However, in the absence of wtHSV-1, ECFP
ﬂuorescent S/G2-phase cells progressed through mitosis to G1 phase at a signiﬁcantly
higher frequency when infected with scAAVCFP than when infected with rAAVCFPNeo
(Fig. 7C).
Overall, we conclude that (i) HSV-1 is not capable of extending its ability to replicate
in all phases of the cell cycle to AAV2, (ii) cell cycle-dependent AAV2 DNA replication
and inhibition of HSV-1 DNA replication are due to cell cycle-dependent AAV2 rep
expression, and (iii) second-strand synthesis is likely not responsible for the cell cycle
preference because both single-stranded and double-stranded linear AAV2 genomes
preferentially transduce cells in S/G2 phase.
DISCUSSION
In this study, we addressed the question of how AAV2 and HSV-1 coordinate their
replication programs. For this, we used a ﬂuorescence microscopy approach, scoring
different cell cycle stages and viral RCs on a single-cell level, and combined the results
with biochemical virus replication measurements in isolated cells at the G1 and S/G2
stages. We ﬁnd that AAV2 replication occurs predominantly in S/G2 phase. Also, AAV2
gene expression was restricted to S/G2-phase cells in both the presence and absence
of the helper virus. HSV-1 replication was in turn restricted to G1-phase cells in
coinfected cultures, while it replicated efﬁciently in both G1- and S/G2-phase cells in the
absence of AAV2 (for an overview, see Tables 2 and 3). On the other hand, HSV-1 RCs
were readily detected in S/G2-phase cells transduced with a rep-negative recombinant
AAV2 vector. Therefore, as Rep proteins are essential for AAV2 replication and have
been found to be at least partially responsible for the AAV2-mediated inhibition of
HSV-1 replication (38, 43, 44), we conclude that cell cycle-dependent AAV2 rep expres-
sion is responsible for the observed restriction of AAV2 replication to S/G2-phase cells
and of HSV-1 replication to G1-phase cells.
We have previously shown that the AAV2 Rep68/78 proteins, in particular the
FIG 6 Legend (Continued)
indicate cells positive for AAV2 RCs and either the red ﬂuorescent G1-phase marker Cdt1 (I) or the green ﬂuorescent S/G2-phase marker geminin
(II). Bars  40 m (left) and 10 m (right). (C) HeLa Fucci cells were transfected with pAAVCFPRep and 4 h later were mock infected or infected
with wtHSV-1 (MOI of 2). After 24 h, extrachromosomal DNA was prepared from Cdt1-positive G1-phase cells (red) and geminin-positive
S/G2-phase cells (green), digested with DpnI, and subjected to qPCR with primers speciﬁc for AAV2 rep. (D) HeLa Fucci cells were transfected with
pAAVCFPRep or pAAVCFPp5 and infected 4 h later with wtHSV-1 (MOI of 2). Total DNA extracted after 24 h from ECFP (AAV2)- and Cdt1 (G1-phase)
(red)- or ECFP- and geminin (S/G2-phase) (green)-double-positive cells was subjected to qPCR with primers speciﬁc for HSV-1 DNA. Graphs in
panels C and D show mean values for relative DNA quantities from triplicate experiments, and samples were prepared from equal numbers of
cells; error bars indicate standard deviations of the means.
AAV2 and HSV-1 Replicate in Distinct Cells Journal of Virology
August 2017 Volume 91 Issue 15 e00357-17 jvi.asm.org 11
 o
n







FIG 7 Live-cell imaging of cell cycle-dependent AAV2 gene expression. (A) HeLa Fucci cells were infected with scAAVCFP (MOI of 3,000) or rAAVCFPNeo
(MOI of 3,000) in the absence or presence of wtHSV-1 (MOI of 3), and images were acquired every 30 min from 2 to 20 h after infection by automated
time-lapse (37°C with 5% CO2, humidiﬁed) epiﬂuorescence microscopy using ImageXpress Micro XL (Molecular Devices) and ﬂuorescence ﬁlters (Semrock)
for ECFP (AAV2 gene expression), GFP (G2 phase), and TRITC (G1 phase). A total of 36 frames was acquired, and the frame numbers are indicated. Overview
images are shown in the left panels. Two different positions highlighted in each of the overview images (boxes 1 and 2) were enlarged and tracked over
time (right panels). Arrows point to cells from the moment when ECFP ﬂuorescence becomes visible. (B) Graph showing the percentage of cells that
turned ECFP positive in either the G1 or S/G2 phase. (C) Graph showing the percentage of transgene-positive S/G2-phase cells progressing to G1 phase.
Both graphs show mean values from at least 100 ECFP-positive cells tracked in at least 9 different infection-and-acquisition experiments; error bars
indicate standard deviations of the means.
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combined DNA-binding and ATPase/helicase activities, can block HSV-1 DNA replica-
tion on the level of DNA synthesis, even in the absence of AAV2 DNA. We also
demonstrated that AAV2 Rep68 can bind to consensus Rep-binding sites on the HSV-1
genome and that the helicase activity can block the replication of any DNA if binding
is facilitated (44). However, the conclusion from the present study, that the inhibition
of HSV-1 replication is limited to S/G2-phase cells because AAV2 rep is expressed
efﬁciently only in this phase, inevitably begs the question of what controls the cell
cycle-dependent expression of rep. Recombinant AAV2 vectors have been reported to
transduce cells predominantly in S phase in the absence of a helper virus (47, 48). Our
ﬁnding that HSV-1-provided helper functions do not support AAV2 replication and
gene expression in G1 phase, although HSV-1 itself can replicate in G1 and S/G2 phases
and although the HSV-1 protein ICP0 strongly trans-activates AAV2 rep expression,
indicates that a step prior to AAV2 transcription may be blocked. One obvious step is
second-strand synthesis. For example, cellular proteins involved in second-strand syn-
thesis such as polymerases or cofactors may not be available at sufﬁcient concentra-
tions in G1 phase. Likewise, factors that block second-strand synthesis, such as DNA
damage repair proteins, may be abundant or activated in G1 but not in S/G2 phase. We
demonstrate that AAV2 transcription and replication are efﬁcient in S/G2- as well as in
G1-phase cells when the template is a circular double-stranded rather than a linear
single-stranded DNA template, indicating that cell cycle-dependent rep expression may
indeed be due to cell cycle-dependent second-strand synthesis. However, the circular
versus linear state of the two template DNAs as well as the different means of delivery,
transfection versus infection, may also affect transcription in a cell cycle-dependent
manner, possibilities that were further explored by using scAAV2 vectors. If inefﬁcient
second-strand synthesis in G1 phase was solely responsible for the observed cell
cycle-dependent AAV2 replication and gene expression, one would expect that scAAV2
vectors, which can form double-stranded DNA by self-annealing and therefore do not
depend on second-strand synthesis for gene expression, can transduce both G1-and






HSV-1   Fig. 1  3
AAV2   Fig. 2  3
AAV2 (HSV-1 coinfection)   Fig. 1–3, Movie S1
HSV-1 (AAV2 coinfection)   Fig. 3  4
a, efﬁcient DNA replication; , inefﬁcient DNA replication; , no DNA replication (AAV2 rep expression
from the p5 promoter).












ssAAV2cmv    Fig. 7, Movie S3
ssAAV2cmv (HSV-1
coinfection)
   Fig. 5  7
ssAAV2p5   ND Table 1
dsAAV2cmv    Fig. 7, Movie S2
dsAAV2cmv (HSV-1
coinfection)
   Fig. 7
assAAV2cmv, single-stranded AAV2 with a cytomegalovirus IE1 enhancer/promoter; dsAAV2cmv, double-
stranded AAV2 with a cytomegalovirus IE1 enhancer/promoter; p5, AAV2 p5 promoter; , efﬁcient
gene expression/G2-to-M-to-G1-phase transition; , inefﬁcient replication/G2-to-M-to-G1-phase transition;
ND, not done.
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S/G2-phase cells efﬁciently. Indeed, in scAAV2 vector-transduced cell cultures, we
observed a considerable proportion of AAV2 transgene-positive G1-phase cells in
the absence of the helper virus, but interestingly, high-throughput multichannel
time-lapse microscopy of cell cycle progression and viral gene expression showed
that the majority of the scAAV2-transduced G1-phase cells originated from scAAV2-
transduced S/G2-phase cells that progressed through mitosis, an event that was
observed at a signiﬁcantly lower rate upon infection with the single-stranded rAAV2
vector (for an overview, see Table 3). We hypothesize that rAAV2 vectors, similar to
wtAAV2 (53), can induce cell cycle arrest more efﬁciently than the scAAV2 vectors
because of the single-stranded versus double-stranded nature of the genome. In
the presence of the helper virus, neither single-stranded nor double-stranded AAV2
vector-transduced cells progressed through mitosis, presumably because of HSV-
1-induced G2 arrest (33). This hypothesis is supported by the ﬁnding that coinfection
with an ICP0 deletion mutant of HSV-1, which is replication competent but does not induce
cell cycle arrest in G2 phase (33), allowed scAAV2 vector-transduced G2-phase cells but
not rAAV2 vector-transduced G2-phase cells to progress through mitosis (data not
shown).
The ﬁndings in this study may have important implications for AAV2-mediated gene
therapy. Both single-stranded and double-stranded AAV2 vectors depend on cells in
S/G2 phase for efﬁcient gene expression, which in fact may contribute to their low
transduction efﬁciency, at least in postmitotic cells. However, when the target cells are
mitotically active, the double-stranded AAV2 vectors may be preferred, as they allow
the cells to go through mitosis, while the single-stranded AAV2 vectors do not. On the
other hand, scAAV2 vectors have been shown to induce a more robust innate immune
response in mouse liver than rAAV2 vectors (54). In any event, it would be interesting
to compare the effects of scAAV2 and rAAV2 vectors on speciﬁc factors involved in cell
cycle regulation, including p53, retinoblastoma protein, cyclin-dependent kinases
(CDKs), and CDK inhibitors.
The observation that both single-stranded and double-stranded AAV2 vectors trans-
duce cells predominantly in S/G2 phase argues against second-strand synthesis as the
mechanism responsible for cell cycle-dependent AAV2 gene expression/DNA replica-
tion and inhibition of HSV-1 DNA replication. Nevertheless, the preference of AAV2 to
transduce cells in the S/G2 phase of the cell cycle may likely be orchestrated by cellular
factors other than those involved in second-strand synthesis. In fact, many different
cellular proteins are recruited to AAV2 genomes (32, 55–57). Among these, the DNA
damage response (DDR) proteins represent a very prominent group and may differen-
tially affect speciﬁc phases in AAV2 genome processing, such as circularization, repli-
cation, and transcription. The DNA damage response is closely linked with the cell cycle
through checkpoint proteins. Moreover, there is increasing evidence that CDKs, which
are the master regulators of cell cycle progression, also have a role in the regulation of
the DNA damage repair (for reviews, see reference 58–60), thereby coordinating DNA
repair and cell cycle progression. For example, it has been shown that CDK1 activity
regulates the choice between different double-strand break (DSB) repair pathways,
homologous recombination (HR) and nonhomologous end joining (NHEJ). In G1 phase,
CDK1 activity is low, and NHEJ is used, while in S/G2/M phase, CDK1 activity is high, and
HR is employed (61, 62). CDK1 activity stimulates HR by promoting the generation of
the 3= single-stranded DNA ends, which are necessary for HR and inhibitory for NHEJ
(61–63). It has also been shown that CDK activity is essential for later steps in HR,
speciﬁcally in the recruitment of Rad51 (64). Functional roles in DNA damage repair
pathways have also been demonstrated for other CDKs in complex with cyclins (for a
review, see reference 65).
The licensing factor that allows AAV2 gene expression/DNA replication in S/G2
phase or the inhibitor that blocks it in G1 phase remains to be identiﬁed. Nevertheless,
the “partitioning” of the host cell population between the two different viruses is a
novel concept of viral adaptation and a fascinating strategy to minimize competition,
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allowing both AAV2 and HSV-1 to productively replicate although in distinct sets of
cells.
MATERIALS AND METHODS
Cells. NHF cells were obtained from X. O. Breakeﬁeld (Massachusetts General Hospital, Charlestown,
MA, USA). HeLa Fucci cells were a gift from B. Kraus (University of Regensburg, Regensburg, Germany);
these cells encode cell cycle-speciﬁc proteins fused with red ﬂuorescent (Cdt1) (G1-phase) or green
ﬂuorescent (geminin) (S/G2-phase) fusion proteins (45). HCT116 cells were provided by E. Hendrickson
(University of Minnesota, Minneapolis, MN, USA). NHF, HeLa Fucci, HCT116, and HeLa (ATCC) cells were
cultured in Dulbecco’s modiﬁed Eagle medium (DMEM) supplemented with 10% fetal bovine serum
(FBS), 100 U/ml penicillin G, 100 g/ml streptomycin, and 0.25 g/ml amphotericin B (1% AB). AT22 IJE-T
yZ5 cells (kindly provided by Y. Shiloh, Tel Aviv University, Tel Aviv, Israel) were cultured in DMEM
supplemented with 10% FBS, 1% AB, and 100 g/ml hygromycin B. Vero cells (ECACC) and 293T cells
(kindly provided by J. Neidhardt, University of Zurich, Zurich, Switzerland) were grown in DMEM
supplemented with 10% FBS and 1% AB. All cells were maintained at 37°C in a 95% air–5% CO2
atmosphere. For all infection experiments, the virus was allowed to adsorb for 30 min at 4°C before the
temperature was shifted to 37°C for 1 h. The cells were then washed with phosphate-buffered saline
(PBS) and incubated with DMEM containing 2% FBS and 1% AB at 37°C for the indicated times after
infection.
Plasmids and viruses. wtHSV-1 strain F was provided by B. Roizman (University of Chicago, Chicago,
IL). Recombinant HSV-1 encoding ICP4 fused with ECFP (rHSV-1vECFP-ICP4) (46) was obtained from R. D.
Everett (University of Glasgow, Glasgow, UK). Recombinant HSV-1 rHSV48EYFP encoding the VP16
protein fused with EYFP was described previously (50). wtHSV-1 and recombinant HSV-1 were grown and
titrated on Vero cells. Plasmid pAAVtCR, which contains a recombinant AAV2 genome that lacks the cap
gene and encodes unmodiﬁed Rep40/52 under the control of the p19 promoter and Rep68/78 fused at
the N terminus with the ﬂuorescent protein mCherry (31) under the control of the p5 promoter, was
obtained from A. Salvetti (University of Lyon, Lyon, France). Plasmids containing recombinant AAV2
genomes, pAAVCFPRep and pAAVYFPRep, were constructed by replacing the mCherry coding sequence
in the pAAVtCR plasmid with ECFP and EYFP coding sequences, respectively, as follows: pAAVtCR was
treated ﬁrst with BsrGI and then partially with BamHI, and the 5,169-bp fragment was ligated with the
738-bp BsrGI-BamHI fragment containing the ECFP or EYFP coding sequences from pECFP-N2 or
pEYFP-N2 (Clontech), respectively. Plasmid pAAVCFPp5, which encodes ECFP from the AAV2 p5 pro-
moter, was constructed by replacing the 1,885-bp BsrGI-SwaI fragment of pAAVCFPRep, which contains
the AAV2 Rep coding sequence, with the BsrG1-SwaI adaptor oligonucleotide 5=-GTACAAGATCGATATT
T-3=. The recombinant AAV2 genome rAAVCFPNeo was constructed by replacing the enhanced green
ﬂuorescent protein (EGFP) coding sequence in plasmid pAAVGFP (provided by M. Linden, King’s College
London School of Medicine, London, UK) with the ECFP coding sequence, as follows: pECFP-N2 was
treated with PstI and NotI, and the 768-bp fragment was ligated with the 6,417-bp PstI-NotI fragment of
pAAVGFP. Transgene expression from pAAVCFPNeo is controlled by the human CMV IE1 enhancer/
promoter. Plasmid pscAAVCFP, which encodes the self-complementary recombinant AAV2 genome
scAAVCFP, was constructed by replacing the EGFP coding sequence in pscAAVeGFP (kindly provided by
J. Neidhardt, University of Zurich, Switzerland) with the ECFP coding sequence. Speciﬁcally, a DNA
fragment containing the CMV enhancer/promoter-ECFP coding sequence was ampliﬁed by PCR from
plasmid pCMVeCFP-PolyA (our unpublished data) using forward (5=-AAGATATCACTAGTTAGTTATTAATA
GTAATCAATTACG-3=) and reverse (5=-CCGGTACCATGCAGTGAAAAAAATGC-3=) primers (PCR conditions
were 30 s at 98°C; 35 cycles of 10 s at 98°C, 45 s at 58°C, and 60 s at 72°C; and 10 min at 72°C), digested
with SpeI and NotI, and ligated between the SpeI and NotI sites of pscAAVeGFP. Recombinant AAV2
stocks were produced by transient transfection of 293T cells with pDG (66) and either pAAVCFPRep,
pAAVYFPRep, pAAVCFPNeo, or pscAAVCFP. Virus stocks were puriﬁed by an iodixanol gradient, and titers
were determined as described previously (67). wtAAV2 was grown and titrated as described previously
(68).
Antibodies. The following primary antibodies were used: antiactin (catalog number SC-10731; Santa
Cruz Biotechnology) (dilution for WB, 1:10,000), anti-ICP8 (catalog number Ab-20193; Abcam) (dilution for
WB, 1:1,000; dilution for immunoﬂuorescence [IF] assays, 1:200), anti-AAV2 Rep (catalog number 10R-
A111A; Fitzgerald Industries) (dilution for WB, 1:200; dilution for IF assays, 1:50), and anti-ICP0 (catalog
number ab6513) (dilution for WB, 1:2,000). The following secondary antibodies were used: rabbit
anti-mouse IgG-horseradish peroxidase (HRP) (catalog number A9044; Sigma) (dilution, 1:10,000), goat
anti-rabbit IgG-HRP (catalog number A6154; Sigma) (dilution, 1:10,000), and goat anti-mouse IgG(HL)–
AF-405 (catalog number A31556; Molecular Probes) (dilution, 1:500).
FACS analysis followed by Western blotting, Southern blotting, or quantitative PCR. For the
experiments in Fig. 3, 5  106 HeLa Fucci cells were seeded onto 10-cm tissue culture plates and 24 h
later were mock infected, infected with wtAAV2 (multiplicity of infection [MOI] of 8,000 genome-
containing particles per cell) or wtHSV-1 (MOI of 3), or coinfected with wtAAV2 (MOI of 8,000) and
wtHSV-1 (MOI of 3). After 24 h, cells positive for Cdt1 (G1 phase) (red) or geminin (S/G2 phase) (green)
were sorted by using a FACSAria III sorter (BD Biosciences) and prepared for Western analysis, Southern
blotting, or qPCR. For Western blot analysis, cells were trypsinized, washed once with PBS, resuspended
in 1 loading buffer (4% SDS, 10% -mercaptoethanol, 20% glycerol, 0.005% bromphenol blue, 0.125 M
Tris-HCl [pH 6.8]), and boiled for 10 min. Cell lysates were separated on 10% SDS-polyacrylamide gels and
transferred onto Protran nitrocellulose membranes (Whatman, Bottmingen, Switzerland). The mem-
branes were blocked with PBS-T (PBS containing 0.3% Tween 20) supplemented with 5% nonfat dry milk
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for 1 h at room temperature (RT). Incubation with antibodies was carried out with PBS-T supplemented
with 2.5% nonfat dry milk. Primary antibodies were incubated overnight at 4°C, while secondary
antibodies were incubated for 1 h at RT. Membranes were washed three times with PBS-T for 10 min after
each antibody incubation step. HRP-conjugated secondary antibodies were detected with ECL detection
reagent (ECL WB blotting systems; GE Healthcare, Zurich, Switzerland). The membranes were exposed to
chemiluminescence detection ﬁlms (Roche Diagnostics, Rotkreuz, Switzerland). Detection of antiactin
served as a loading control for the lysate. For Southern blot analysis, extrachromosomal DNA was
extracted according to protocols described previously by Hirt (52). The DNA was separated on 1%
agarose gels and transferred onto nylon membranes (Hybond-N, catalog number RPN119B; Amersham).
Hybridization with a digoxigenin (DIG)-labeled probe speciﬁc for the AAV2 Rep78- or the HSV-1
UL35-coding sequences and subsequent detection by an anti-DIG antibody conjugated with alkaline
phosphatase and activation with the chemiluminescence substrate CDP Star were performed according
to the manufacturer’s protocols (Roche, Mannheim, Germany). The DIG-labeled probe was produced with
the PCR DIG probe synthesis kit (Roche). For qPCR, total DNA was isolated by using the DNeasy blood
and tissue kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. The viral DNA content
was quantiﬁed by qPCR using the cellular telomerase reverse transcriptase (TERT) gene as an endoge-
nous control (Applied Biosystems, Foster City, CA, USA) and primers and a TaqMan probe speciﬁc for the
AAV2 Rep78-coding sequence (forward primer 5=-ATTGACGGAACTCAACGAC-3=, reverse primer 5=-CCTC
AACCACGTCCTTT-3=, and TaqMan probe 5=-CATGATCCAGACGGCGGGTGA-3=) or primers speciﬁc for the
HSV-1 UL42 gene (forward primer 5=-CCCTCAAGTTCTTCTTCCTCACG-3= and reverse primer 5=-GGAGTCC
TGGCTGTCTGTTG-3=) and SYBR green (Applied Biosystems, Foster City, CA, USA). AAV2 sequences were
ampliﬁed under the following conditions: 2 min at 50°C; 15 min at 95°C; and 40 cycles of 15 s at 94°C,
30 s at 56°C, and 15 s at 72°C. HSV-1 sequences were ampliﬁed under the following conditions: 3 min at
95°C, 39 cycles of 15 s at 95°C and 60 s at 45°C, 10 s at 95°C, 5 s at 65°C, and 5 s at 95°C. For the
experiments shown in Fig. 7C and D, 1.5  106 HeLa Fucci cells in 6-cm tissue culture plates were
transfected with 0.5 g of either pAAVCFPRep or pAAVCFPp5 by using Lipofectamine LTX according to
the manufacturer’s instructions (Life Technologies) and 4 h later were mock-infected or infected with
wtHSV-1 (MOI of 2) as described in the legend. After 24 h, cells positive for the G1-phase marker Cdt1
(red) or double positive for the G1-phase marker and either CFP-Rep or CFP were sorted by using a
FACSAria III sorter (BD Biosciences). Hirt DNA or total DNA was then prepared from the sorted cell
populations. To determine the AAV2 DNA content, Hirt DNA was incubated with DpnI prior to qPCRs in
order to degrade the transfected input plasmid DNA isolated from Escherichia coli. To determine the
HSV-1 DNA content, total DNA was used for qPCR.
Microscopy. For microscopy, HeLa or HeLa Fucci cells were seeded onto coverslips (12-mm diameter;
Glaswarenfabrik Karl Hecht GmbH & Co. KG, Sondheim, Germany) in 24-well tissue culture plates (5 104
cells per well) or, speciﬁcally for epiﬂuorescence live-cell microscopy, directly onto 96-well tissue culture
plates (104 cells per well) (see also reference 69). The next day, the cells were infected as indicated in
Results and the ﬁgure legends. For the experiments shown in Fig. 6, the cells were transfected with
0.5 g of either pAAVCFPRep or pAAVCFPp5 4 h prior to infection. For live-cell microscopy of AAV2 gene
expression/replication and cell cycle progression (Fig. 5A and 7A; see also Movies S1 to S3 in the
supplemental material), images were acquired every 30 min from 2 to 20 h after infection by automated
multisite multichannel live epiﬂuorescence microscopy in a time-lapse mode (37°C with 5% CO2,
humidiﬁed) by using ImageXpress Micro XL (Molecular Devices) and ﬂuorescence ﬁlters (Semrock) for
ECFP (AAV2), GFP (G2 phase), and tetramethylrhodamine isocyanate (TRITC) (G1 phase) (69, 70); images
were processed by using Fiji software (71). For standard ﬂuorescence microscopy or CSLM, the cells were
washed once with cold PBS 24 h after infection and then ﬁxed with 3.7% paraformaldehyde (PFA) in PBS
for 10 min at RT. The ﬁxation process was stopped by incubation with 0.1 M glycine for 10 min at RT and
two washes with cold PBS. For immunoﬂuorescence analysis (Fig. 1A and B), the cells were permeabilized
by treatment with precooled (20°C) acetone for 2 min, followed by 3 washing steps with PBS. The cells
were blocked for 30 min with 3% bovine serum albumin (BSA) in PBS. For staining, the cells were
incubated with antibodies diluted in PBS-BSA (3%) in a humidiﬁed chamber at RT in the dark. The
coverslips were placed onto droplets (40 l) of a primary antibody solution. After incubation for 1 h,
the cells were washed three times with PBS and once with H2O. All coverslips (with and without anti-
body staining) were embedded in Glycergel (DakoCytomation, Carpinteria, CA) containing 1,4-
diazabicyclo[2.2.2]octan (DABCO) (26 mg/ml; Fluka, Sigma-Aldrich Chemie GmbH, Munich, Germany),
and cells were observed by using a confocal laser scanning microscope (Leica TCS SP2 acousto-optical
beam splitter (AOBS); Leica Microsystems, Wetzlar, Germany) (Fig. 1A and B and 6A and B), an automated
epiﬂuorescence microscope using ImageXpress Micro XL (Molecular Devices) (Fig. 5A), or a standard
ﬂuorescence microscope (Axio Observer inverted microscope, Zeiss AG, Germany) (Fig. 5C). To prevent
cross talk between the channels for the different ﬂuorochromes, all channels were recorded separately,
and ﬂuorochromes with longer wavelengths were recorded ﬁrst.
Flow cytometry. HCT116, AT22, NHF, or HeLa Fucci cells were seeded into wells of a 12-well tissue
culture plate (105 cells per well) and 24 h later were coinfected with wtHSV-1 (MOI of 1.5 for AT22 cells
and MOI of 3 for all other cell lines) and either rAAVCFPRep or rAAVYFPRep (MOI of 1,000 for HeLa Fucci
cells and MOI of 4,000 for all other cell lines), as indicated in Table 1. All cells were incubated at 37°C with
5% CO2 in DMEM supplemented with 2% FBS and 1% AB. After 20 to 24 h, the cells were trypsinized,
washed once with PBS, centrifuged for 10 min at 1,000  g, and resuspended in 1 ml PBS. The cells were
ﬁxed by the addition of 2.5 ml ethanol (EtOH) and incubation overnight at 20°C. To determine the cell
cycle phases in HCT116, NHF, and AT22 cells, DNA was stained for 30 min with DAPI (1 g/ml in PBS
containing 0.1% Triton X-100) or propidium iodide (PI) (50 g/ml in PBS containing 0.1% Triton X-100 and
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0.1 mg/ml RNase A), as indicated in Table 1. A minimum of 40,000 events were scored for each sample
by using a Gallios ﬂow cytometer (Beckman Coulter), and data were analyzed by using Kaluza Flow
Analysis software 1.3 (Beckman Coulter).
Fluorescence in situ hybridization. FISH was performed essentially as described previously by Lux
et al. (68). Brieﬂy, an 3.9-kb DNA fragment containing the AAV2 genome without the inverted terminal
repeats was ampliﬁed by PCR from plasmid pDG (66) using forward (5=-CGGGGTTTTACGAGATTGTG-3=)
and reverse (5=-GGCTCTGAATACACGCCATT-3=) primers and the following conditions: 30 s at 95°C; 35
cycles of 10 s at 98°C, 15 s at 58°C, and 75 s at 72°C; and 10 min at 72°C. The PCR product was then
digested with DpnI to cut the residual template DNA and puriﬁed with a Pure Link PCR puriﬁcation kit
(Qiagen). The DNA fragment was labeled with 5-(3-aminoallyl)dUTP by nick translation, and the incor-
porated dUTPs were labeled with amino-reactive Alexa Fluor 647 dye by using the Ares DNA labeling kit
(Molecular Probes) according to the manufacturer’s protocols. HeLa Fucci cells were plated onto glass
coverslips in 24-well plates at a density of 1.4  105 cells per well and 24 h later were mock infected,
infected with wtAAV2 (MOI of 4,000), or coinfected with wtAAV2 (MOI of 4,000) and either wtHSV-1 (MOI
of 3) or rHSV-1vECFP-ICP4 (MOI of 3). Twenty-four hours after infection, the cells were washed with PBS,
ﬁxed for 30 min at RT with 2% PFA (in PBS), and then washed again with PBS. The cells were then
quenched for 10 min with 50 mM NH4Cl (in PBS), washed with PBS, permeabilized for 10 min with 0.2%
Triton X-100 (in PBS), blocked for 10 min with 0.2% gelatin (in PBS), and washed again with PBS.
Hybridization solution (20 l per coverslip) containing 1 ng/l of the labeled DNA probe, 50% form-
amide, 7.3% dextran sulfate, 15 ng/l salmon sperm DNA, and 0.74 SSC (1 SSC is 0.15 M NaCl plus
0.015 M sodium citrate) was denatured for 3 min at 95°C and shock cooled on ice. The coverslips with
the ﬁxed, and permeabilized cells facing down were placed onto a drop (20 l) of the denatured
hybridization solution and incubated overnight at 37°C in a humidiﬁed chamber. (Of note, the cells were
not denatured, as the AAV2 genome is a single-stranded DNA.) The next day, the coverslips were washed
three times with 2 SSC at 37°C, three times with 0.1 SSC at 60°C, and twice with PBS at RT. The cells
were then embedded in ProLong Anti-Fade mountant (Molecular Probes) and imaged by confocal laser
scanning microscopy (Leica SP8; Leica Microsystems, Wetzlar, Germany).
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/JVI
.00357-17.
SUPPLEMENTAL FILE 1, MP4 ﬁle, 0.3 MB.
SUPPLEMENTAL FILE 2, MP4 ﬁle, 0.2 MB.
SUPPLEMENTAL FILE 3, MP4 ﬁle, 0.2 MB.
SUPPLEMENTAL FILE 4, PDF ﬁle, 0.1 MB.
ACKNOWLEDGMENTS
We thank X. O. Breakeﬁeld, B. Kraus, E. Hendrickson, Y. Shiloh, J. Neidhardt, B.
Roizman, R. Everett, A. Salvetti, and M. Linden for providing reagents and E. M. Schraner
for assistance with the preparation of the ﬁgures.
This work was supported by grants 31003A_144094/1 and 31003A_166668/1 from
the Swiss National Science Foundation to C.F.
We declare that we have no conﬂict of interest.
REFERENCES
1. Adeyemi RO, Pintel DJ. 2014. Parvovirus-induced depletion of cyclin B1
prevents mitotic entry of infected cells. PLoS Pathog 10:e1003891.
https://doi.org/10.1371/journal.ppat.1003891.
2. Berk AJ. 2007. Adenoviridae: the viruses and their replication, p
2355–2394. In Knipe DM, Howley PM, Grifﬁn DE, Lamb RA, Martin MA,
Roizman B, Straus SE (ed), Fields virology, 5th ed. Lippincott Williams &
Wilkins, Philadelphia, PA.
3. Aubert M, Chen Z, Lang R, Dang CH, Fowler C, Sloan DD, Jerome KR.
2008. The antiapoptotic herpes simplex virus glycoprotein J localizes to
multiple cellular organelles and induces reactive oxygen species forma-
tion. J Virol 82:617–629. https://doi.org/10.1128/JVI.01341-07.
4. Taylor TJ, Brockman MA, McNamee EE, Knipe DM. 2002. Herpes simplex
virus. Front Biosci 7:d752–d764. https://doi.org/10.2741/A809.
5. Hobbs WE, II, DeLuca NA. 1999. Perturbation of cell cycle progression
and cellular gene expression as a function of herpes simplex virus ICP0.
J Virol 73:8245–8255.
6. Ehmann GL, McLean TI, Bachenheimer SL. 2000. Herpes simplex virus
type 1 infection imposes a G(1)/S block in asynchronously growing cells
and prevents G(1) entry in quiescent cells. Virology 267:335–349. https://
doi.org/10.1006/viro.1999.0147.
7. Lomonte P, Everett RD. 1999. Herpes simplex virus type 1 immediate-
early protein Vmw110 inhibits progression of cells through mitosis and
from G(1) into S phase of the cell cycle. J Virol 73:9456–9467.
8. Song B, Liu JJ, Yeh KC, Knipe DM. 2000. Herpes simplex virus infection
blocks events in the G1 phase of the cell cycle. Virology 267:326–334.
https://doi.org/10.1006/viro.1999.0146.
9. Song B, Yeh KC, Liu J, Knipe DM. 2001. Herpes simplex virus gene
products required for viral inhibition of expression of G1-phase func-
tions. Virology 290:320–328. https://doi.org/10.1006/viro.2001.1175.
10. Muzyczka N, Berns KI. 2001. Parvoviridae: the viruses and their replica-
tion, p 2327–2346. In Knipe DM, Howley PM, Grifﬁn DE, Lamb RA, Martin
MA, Roizman B, Straus SE (ed), Fields virology, 4th ed, vol 2. Lippincott
Williams & Wilkins, Philadelphia, PA.
11. Sonntag F, Schmidt K, Kleinschmidt JA. 2010. A viral assembly factor
promotes AAV2 capsid formation in the nucleolus. Proc Natl Acad Sci
U S A 107:10220–10225. https://doi.org/10.1073/pnas.1001673107.
12. Chejanovsky N, Carter BJ. 1989. Mutagenesis of an AUG codon in the
adeno-associated virus rep gene: effects on viral DNA replication. Virol-
ogy 173:120–128. https://doi.org/10.1016/0042-6822(89)90227-4.
13. Im DS, Muzyczka N. 1990. The AAV origin binding protein Rep68 is an
ATP-dependent site-speciﬁc endonuclease with DNA helicase activ-
ity. Cell 61:447–457. https://doi.org/10.1016/0092-8674(90)90526-K.
AAV2 and HSV-1 Replicate in Distinct Cells Journal of Virology
August 2017 Volume 91 Issue 15 e00357-17 jvi.asm.org 17
 o
n







14. Kotin RM, Menninger JC, Ward DC, Berns KI. 1991. Mapping and direct
visualization of a region-speciﬁc viral DNA integration site on chromo-
some 19q13-qter. Genomics 10:831–834. https://doi.org/10.1016/0888
-7543(91)90470-Y.
15. Samulski RJ, Zhu X, Xiao X, Brook JD, Housman DE, Epstein N, Hunter LA.
1991. Targeted integration of adeno-associated virus (AAV) into human
chromosome 19. EMBO J 10:3941–3950. (Erratum, 11:1228, 1992).
16. King JA. 2001. DNA helicase-mediated packaging of adeno-associated
virus type 2 genomes into preformed capsids. EMBO J 20:3282–3291.
https://doi.org/10.1093/emboj/20.12.3282.
17. McCarty DM, Young SMJ, Samulski RJ. 2004. Integration of adeno-
associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet
38:819–845. https://doi.org/10.1146/annurev.genet.37.110801.143717.
18. Smith RH, Kotin RM. 1998. The Rep52 gene product of adeno-associated
virus is a DNA helicase with 3=-to-5= polarity. J Virol 72:4874–4881.
19. Wu J, Davis MD, Owens RA. 1999. Factors affecting the terminal resolution
site endonuclease, helicase, and ATPase activities of adeno-associated virus
type 2 Rep proteins. J Virol 73:8235–8244.
20. Zhou X, Zolotukhin I, Im DS, Muzyczka N. 1999. Biochemical character-
ization of adeno-associated virus rep68 DNA helicase and ATPase activ-
ities. J Virol 73:1580–1590.
21. Yoon-Robarts M, Linden RM. 2003. Identiﬁcation of active site residues of
the adeno-associated virus type 2 Rep endonuclease. J Biol Chem 278:
4912–4918. https://doi.org/10.1074/jbc.M209750200.
22. Collaco RF, Kalman-Maltese V, Smith AD, Dignam JD, Trempe JP.
2003. A biochemical characterization of the adeno-associated virus
Rep40 helicase. J Biol Chem 278:34011–34017. https://doi.org/10
.1074/jbc.M301537200.
23. Hoggan MD, Blacklow NR, Rowe WP. 1966. Studies of small DNA viruses
found in various adenovirus preparations: physical, biological, and im-
munological characteristics. Proc Natl Acad Sci U S A 55:1467–1474.
https://doi.org/10.1073/pnas.55.6.1467.
24. Buller RM, Janik JE, Sebring ED, Rose JA. 1981. Herpes simplex virus types
1 and 2 completely help adenovirus-associated virus replication. J Virol
40:241–247.
25. Walz C, Deprez A, Dupressoir T, Dürst M, Rabreau M, Schlehofer JR. 1997.
Interaction of human papillomavirus type 16 and adeno-associated virus
type 2 co-infecting human cervical epithelium. J Gen Virol 78(Part
6):1441–1452.
26. Kotin RM, Linden RM, Berns KI. 1992. Characterization of a preferred site
on human chromosome 19q for integration of adeno-associated virus
DNA by non-homologous recombination. EMBO J 11:5071–5078.
27. Linden RM, Ward P, Giraud C, Winocour E, Berns KI. 1996. Site-speciﬁc
integration by adeno-associated virus. Proc Natl Acad Sci U S A 93:
11288–11294. https://doi.org/10.1073/pnas.93.21.11288.
28. Linden RM, Winocour E, Berns KI. 1996. The recombination signals for
adeno-associated virus site-speciﬁc integration. Proc Natl Acad Sci U S A
93:7966–7972. https://doi.org/10.1073/pnas.93.15.7966.
29. Weindler FW, Heilbronn R. 1991. A subset of herpes simplex virus
replication genes provides helper functions for productive adeno-
associated virus replication. J Virol 65:2476–2483.
30. Ward P, Falkenberg M, Elias P, Weitzman M, Linden RM. 2001. Rep-
dependent initiation of adeno-associated virus type 2 DNA replication
by a herpes simplex virus type 1 replication complex in a reconstituted
system. J Virol 75:10250–10258. https://doi.org/10.1128/JVI.75.21.10250
-10258.2001.
31. Alazard-Dany N, Nicolas A, Ploquin A, Strasser R, Greco A, Epstein AL,
Fraefel C, Salvetti A. 2009. Deﬁnition of herpes simplex virus type 1
helper activities for adeno-associated virus early replication events. PLoS
Pathog 5:e1000340. https://doi.org/10.1371/journal.ppat.1000340.
32. Vogel R, Seyffert M, Strasser R, de Oliveira AP, Dresch C, Glauser DL,
Jolinon N, Salvetti A, Weitzman MD, Ackermann M, Fraefel C. 2011.
Adeno-associated virus type 2 modulates the host DNA damage re-
sponse induced by herpes simplex virus 1 during coinfection. J Virol
86:143–155. https://doi.org/10.1128/JVI.05694-11.
33. Li H, Baskaran R, Krisky DM, Bein K, Grandi P, Cohen JB, Glorioso JC. 2008.
Chk2 is required for HSV-1 ICP0-mediated G2/M arrest and enhancement
of virus growth. Virology 375:13–23. https://doi.org/10.1016/j.virol.2008
.01.038.
34. Casto BC, Armstrong JA, Atchison RW, Hammon WM. 1967. Studies on
the relationship between adeno-associated virus type 1 (AAV-1) and
adenoviruses. II. Inhibition of adenovirus plaques by AAV; its nature and
speciﬁcity. Virology 33:452–458. https://doi.org/10.1016/0042-6822
(67)90120-1.
35. Casto BC, Atchison RW, Hammon WM. 1967. Studies on the relationship
between adeno-associated virus type I (AAV-1) and adenoviruses. I.
Replication of AAV-1 in certain cell cultures and its effect on helper
adenovirus. Virology 32:52–59. https://doi.org/10.1016/0042-6822
(67)90251-6.
36. Carter BJ, Laughlin CA, de la Maza LM, Myers M. 1979. Adeno-associated
virus autointerference. Virology 92:449–462. https://doi.org/10.1016/
0042-6822(79)90149-1.
37. Bantel-Schaal U, Zur Hausen H. 1988. Adeno-associated viruses inhibit
SV40 DNA ampliﬁcation and replication of herpes simplex virus in
SV40-transformed hamster cells. Virology 164:64–74. https://doi.org/10
.1016/0042-6822(88)90620-4.
38. Glauser DL, Strasser R, Laimbacher AS, Saydam O, Clément N, Linden RM,
Ackermann M, Fraefel C. 2007. Live covisualization of competing adeno-
associated virus and herpes simplex virus type 1 DNA replication: mo-
lecular mechanisms of interaction. J Virol 81:4732–4743. https://doi.org/
10.1128/JVI.02476-06.
39. Chiorini JA, Zimmermann B, Yang L, Smith RH, Ahearn A, Herberg F,
Kotin RM. 1998. Inhibition of PrKX, a novel protein kinase, and the cyclic
AMP-dependent protein kinase PKA by the regulatory proteins of
adeno-associated virus type 2. Mol Cell Biol 18:5921–5929. https://doi
.org/10.1128/MCB.18.10.5921.
40. Di Pasquale G, Stacey SN. 1998. Adeno-associated virus Rep78 protein
interacts with protein kinase A and its homolog PRKX and inhibits
CREB-dependent transcriptional activation. J Virol 72:7916–7925.
41. Schmidt M, Chiorini JA, Aﬁone S, Kotin R. 2002. Adeno-associated virus
type 2 Rep78 inhibition of PKA and PRKX: ﬁne mapping and analysis of
mechanism. J Virol 76:1033–1042. https://doi.org/10.1128/JVI.76.3.1033
-1042.2002.
42. Di Pasquale G, Chiorini JA. 2003. PKA/PrKX activity is a modulator of
AAV/adenovirus interaction. EMBO J 22:1716–1724. https://doi.org/10
.1093/emboj/cdg153.
43. Glauser DL, Seyffert M, Strasser R, Franchini M, Laimbacher AS, Dresch C,
de Oliveira AP, Vogel R, Büning H, Salvetti A, Ackermann M, Fraefel C.
2010. Inhibition of herpes simplex virus type 1 replication by adeno-
associated virus Rep proteins depends on their combined DNA-binding
and ATPase/helicase activities. J Virol 84:3808–3824. https://doi.org/10
.1128/JVI.01503-09.
44. Seyffert M, Glauser DL, Tobler K, Georgiev O, Vogel R, Vogt B, Agúndez
L, Linden M, Büning H, Ackermann M, Fraefel C. 2015. Adeno-associated
virus type 2 Rep68 can bind to consensus Rep-binding sites on the
herpes simplex virus 1 genome. J Virol 89:11150–11158. https://doi.org/
10.1128/JVI.01370-15.
45. Sakaue-Sawano A, Kurokawa H, Morimura T, Hanyu A, Hama H, Osawa H,
Kashiwagi S, Fukami K, Miyata T, Miyoshi H, Imamura T, Ogawa M, Masai
H, Miyawaki A. 2008. Visualizing spatiotemporal dynamics of multicellu-
lar cell-cycle progression. Cell 132:487–498. https://doi.org/10.1016/j.cell
.2007.12.033.
46. Everett RD, Sourvinos G, Orr A. 2003. Recruitment of herpes simplex virus
type 1 transcriptional regulatory protein ICP4 into foci juxtaposed to
ND10 in live, infected cells. J Virol 77:3680–3689. https://doi.org/10
.1128/JVI.77.6.3680-3689.2003.
47. Russell DW, Miller AD, Alexander IE. 1994. Adeno-associated virus vec-
tors preferentially transduce cells in S phase. Proc Natl Acad Sci U S A
91:8915–8919. https://doi.org/10.1073/pnas.91.19.8915.
48. Russell DW, Alexander IE, Miller AD. 1995. DNA synthesis and topoisom-
erase inhibitors increase transduction by adeno-associated virus vectors.
Proc Natl Acad Sci U S A 92:5719–5723. https://doi.org/10.1073/pnas.92
.12.5719.
49. Glauser DL, Saydam O, Fraefel C. 2006. Parvovirus replication, p 71–99. In
Hefferon KL (ed), Recent advances in DNA virus replication. Research
Signpost, Kerala, India.
50. de Oliveira AP, Glauser DL, Laimbacher AS, Strasser R, Schraner EM, Wild
P, Ziegler U, Breakeﬁeld XO, Ackermann M, Fraefel C. 2008. Live visual-
ization of herpes simplex virus type 1 compartment dynamics. J Virol
82:4974–4990. https://doi.org/10.1128/JVI.02431-07.
51. La Boissiere S, Izeta A, Malcomber S, O’Hare P. 2004. Compartmentaliza-
tion of VP16 in cells infected with recombinant herpes simplex virus
expressing VP16-green ﬂuorescent protein fusion proteins. J Virol 78:
8002–8014. https://doi.org/10.1128/JVI.78.15.8002-8014.2004.
52. Hirt B. 1969. Replicating molecules of polyoma virus DNA. J Mol Biol
40:141–144. https://doi.org/10.1016/0022-2836(69)90302-7.
53. Hermanns J, Schulze A, Jansen-Dürr P, Kleinschmidt JA, Schmidt R, Zur
Hausen H. 1997. Infection of primary cells by adeno-associated virus
Franzoso et al. Journal of Virology
August 2017 Volume 91 Issue 15 e00357-17 jvi.asm.org 18
 o
n







type 2 results in a modulation of cell cycle-regulating proteins. J Virol
71:6020–6027.
54. Martino AT, Suzuki M, Markusic DM, Zolotukhin I, Ryals RC, Moghimi B,
Ertl HC, Muruve DA, Lee B, Herzog RW. 2011. The genome of self-
complementary adeno-associated viral vectors increases Toll-like recep-
tor 9-dependent innate immune responses in the liver. Blood 117:
6459–6468. https://doi.org/10.1182/blood-2010-10-314518.
55. Nash K, Chen W, McDonald WF, Zhou X, Muzyczka N. 2007. Puriﬁcation
of host cell enzymes involved in adeno-associated virus DNA replication.
J Virol 81:5777–5787. https://doi.org/10.1128/JVI.02651-06.
56. Cervelli T, Palacios JA, Zentilin L, Mano M, Schwartz RA, Weitzman MD,
Giacca M. 2008. Processing of recombinant AAV genomes occurs in
speciﬁc nuclear structures that overlap with foci of DNA-damage-
response proteins. J Cell Sci 121:349–357. https://doi.org/10.1242/jcs
.003632.
57. Nicolas A, Alazard-Dany N, Biollay C, Arata L, Jolinon N, Kuhn L, Ferro M,
Weller SK, Epstein AL, Salvetti A, Greco A. 2010. Identiﬁcation of Rep-
associated factors in herpes simplex virus type 1-induced adeno-
associated virus type 2 replication compartments. J Virol 84:8871–8887.
https://doi.org/10.1128/JVI.00725-10.
58. Branzei D, Foiani M. 2008. Regulation of DNA repair throughout the cell
cycle. Nat Rev Mol Cell Biol 9:297–308. https://doi.org/10.1038/nrm2351.
59. You Z, Bailis JM. 2010. DNA damage and decisions: CtIP coordinates DNA
repair and cell cycle checkpoints. Trends Cell Biol 20:402–409. https://
doi.org/10.1016/j.tcb.2010.04.002.
60. Trovesi C, Manfrini N, Falcettoni M, Longhese MP. 2013. Regulation of
the DNA damage response by cyclin-dependent kinases. J Mol Biol
425:4756–4766. https://doi.org/10.1016/j.jmb.2013.04.013.
61. Aylon Y, Liefshitz B, Kupiec M. 2004. The CDK regulates repair of double-
strand breaks by homologous recombination during the cell cycle.
EMBO J 23:4868–4875. https://doi.org/10.1038/sj.emboj.7600469.
62. Ira G, Pellicioli A, Balijja A, Wang X, Fiorani S, Carotenuto W, Liberi G,
Bressan D, Wan L, Hollingsworth NM, Haber JE, Foiani M. 2004. DNA end
resection, homologous recombination and DNA damage checkpoint
activation require CDK1. Nature 431:1011–1017. https://doi.org/10.1038/
nature02964.
63. Zhang Y, Shim EY, Davis M, Lee SE. 2009. Regulation of repair choice:
Cdk1 suppresses recruitment of end joining factors at DNA breaks. DNA
Repair (Amst) 8:1235–1241. https://doi.org/10.1016/j.dnarep.2009.07
.007.
64. Caspari T, Murray JM, Carr AM. 2002. Cdc2-cyclin B kinase activity links
Crb2 and Rqh1-topoisomerase III. Genes Dev 16:1195–1208. https://doi
.org/10.1101/gad.221402.
65. Lim S, Kaldis P. 2013. Cdks, cyclins and CKIs: roles beyond cell cycle
regulation. Development 140:3079–3093. https://doi.org/10.1242/dev
.091744.
66. Grimm D, Kern A, Rittner K, Kleinschmidt JA. 1998. Novel tools for
production and puriﬁcation of recombinant adenoassociated virus vec-
tors. Hum Gene Ther 9:2745–2760. https://doi.org/10.1089/hum.1998.9
.18-2745.
67. Grieger JC, Choi VW, Samulski RJ. 2006. Production and characterization
of adeno-associated viral vectors. Nat Protoc 1:1412–1428. https://doi
.org/10.1038/nprot.2006.207.
68. Lux K, Goerlitz N, Schlemminger S, Perabo L, Goldnau D, Endell J, Leike
K, Koﬂer DM, Finke S, Hallek M, Buning H. 2005. Green ﬂuorescent
protein-tagged adeno-associated virus particles allow the study of cy-
tosolic and nuclear trafﬁcking. J Virol 79:11776–11787. https://doi.org/
10.1128/JVI.79.18.11776-11787.2005.
69. Yakimovich A, Gumpert H, Burckhardt CJ, Lutschg VA, Jurgeit A, Sbal-
zarini IF, Greber UF. 2012. Cell-free transmission of human adenovirus by
passive mass transfer in cell culture simulated in a computer model. J
Virol 86:10123–10137. https://doi.org/10.1128/JVI.01102-12.
70. Yakimovich A, Andriasyan V, Witte R, Wang IH, Prasad V, Suomalainen M,
Greber UF. 2015. Plaque2.0—a high-throughput analysis framework to
score virus-cell transmission and clonal cell expansion. PLoS One 10:
e0138760. https://doi.org/10.1371/journal.pone.0138760.
71. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T,
Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez JY, White DJ,
Hartenstein V, Eliceiri K, Tomancak P, Cardona A. 2012. Fiji: an open-
source platform for biological-image analysis. Nat Methods 9:676–682.
https://doi.org/10.1038/nmeth.2019.
AAV2 and HSV-1 Replicate in Distinct Cells Journal of Virology
August 2017 Volume 91 Issue 15 e00357-17 jvi.asm.org 19
 o
n







5.2. Targeted image-based RNAi screen identifies host cell proteins with 
differential effects on the transduction efficiency of single-stranded and self-
complementary  AAV vectors 
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Adeno­associated  virus  (AAV)  based  vectors  attract  significant  interest  for  gene  therapy. 
Here  we  performed  a  targeted,  small  interfering  RNA  (siRNA)  screen  for  host  factors 
implicated  in  AAV  vector  transduction.  We  identified  cellular  proteins,  which  affected  the 
transduction efficiency of single­stranded (ss) and double­stranded (ds), self­complementary 
(sc) AAV vectors equally, as well as proteins with differential effects on the two vector types. 
In  particular,  knockdown  of  the  ss  DNA  binding  protein  RPA1  resulted  in  differential 
transduction efficiencies of ss and sc AAV vectors. Knockdown of RPA2, another subunit of 
the  RPA  complex,  had  a  similar  effect  as  RPA1  on  vector  transduction.  Interestingly 
however, RPA2 appeared  to enhance HSV­1 mediated AAV2 DNA replication while RPA1 
had no effect. Taken  together,  this study extends  the  list of host  factors  implicated  in AAV 


























































































et  al.,  1966; Walz et  al.,  1997).  In  absence of  the helper  virus, AAV2 establishes a  latent 
infection by maintaining its genome as an episome in the cell nucleus or by integrating it into 
the  host  cell  genome,  preferentially  at  a  site  termed  AAVS1  on  human  chromosome  19 
(Kotin et al., 1992; Kotin et al., 1991; Linden et al., 1996a; Linden et al., 1996b).  
The AAV2 genome is a single­stranded DNA of 4.68 kb containing two clusters of genes, rep 
and cap,  flanked by  inverted  terminal  repeats  (ITRs) of 145 nucleotides. The  ITRs contain 
the  viral  origin  of  DNA  replication  and  packaging  signal. The  rep genes  encode  four Rep 
isoforms,  Rep40,  Rep52,  Rep68,  and Rep78,  due  to  alternative  splicing  and  transcription 
from two different promoters, p5 and p19. The multifunctional Rep proteins are  involved  in 
diverse  processes  of  the  AAV2  life  cycle,  including  DNA  replication,  regulation  of  gene 
expression,  genome  packaging,  and  genomic  integration  (Collaco  et  al.,  2003;  Im  and 
Muzyczka,  1990;  King,  2001;  Smith  and  Kotin,  1998; Wu  et  al.,  1999;  Yoon­Robarts  and 
Linden, 2003; Zhou et al., 1999). The cap genes are expressed from the p40 promoter and 
encode  the VP1,  VP2,  and VP3  proteins, which  differ  in  their N­termini  due  to  alternative 
start codons; together they form an icosahedral capsid of 25 nm in diameter (Muzyczka and 
Berns,  2001).  A  nested  open  reading  frame  within  the  cap  gene  encodes  the  so  called 
assembly­activating protein, which  is believed  to be  required  for AAV2 capsid assembly  in 
the nucleolus (Sonntag et al., 2010). 
The unique  replication strategy of AAV2  is based on a  rolling­hairpin mechanism  in which 
the end of  the 3’­ITR acts as primer  for second­strand synthesis. The asymmetric  leading­
strand DNA  synthesis  results  in  a  closed­end  intermediate  at  the  3'­ITR.  This  structure  is 




































































terminal  resolution signal  (TRS),  thereby creating a primer  that allows completing  the DNA 
replication  process  (Tattersall  and Ward,  1976)  (for  a  review  see:  (Muzyczka  and  Berns, 
2001)). 
Helper virus mediated AAV2 replication takes place in intranuclear replication compartments 
(RCs)  that  contain  AAV2  DNA  as  well  as  viral  and  cellular  proteins  involved  in  AAV2 
genome  processing,  including  second­strand  synthesis,  transcription  and  DNA  replication 
(Alazard­Dany et al., 2009; Cervelli et al., 2008; Fraefel et al., 2004; Franzoso et al., 2017; 
Glauser  et  al.,  2005;  Glauser  et  al.,  2010;  Glauser  et  al.,  2007;  Stracker  et  al.,  2004; 
Weitzman et al.,  1996). Proteomics and  immunofluorescence analyses of  cells  co­infected 
with AAV2 and either AdV5 or HSV­1 revealed numerous cellular proteins that are recruited 
into AAV2 RCs or interact with Rep78 (Nash et al., 2009; Nicolas et al., 2010; Vogel et al., 
2012)  (for a  review see:  (Vogel et al., 2013)).  Independent of  the  type of helper virus,  the 
largest  functional  groups  of  cellular  proteins  recruited  to  AAV2  RCs  belong  to  the  DNA 
replication/repair  machinery  and  transcription/RNA  metabolism.  While  the  majority  of  the 
cellular proteins  in HSV­1 supported AAV2 RCs were  found also  in AdV5 supported AAV2 
RCs,  some proteins were associated with AAV2 RCs only  in presence of  either HSV­1 or 
AdV5.  
The role of most of the cellular components of AAV2 RCs in AAV2 second­strand synthesis, 
transcription,  and  replication  is  not  known.  For  example,  replication  protein  A  (RPA),  a 
heterotrimeric  single­stranded DNA binding protein  complex  composed of RPA1  (70 kDa), 




(Fairman  and Stillman,  1988;  Ishimi  et  al.,  1988; Wold  and Kelly,  1988)  (for  reviews  see: 
(Borowiec et al., 1990; Bullock, 1997; Fanning and Knippers, 1992)). While RPA has been 













































































2012).  The  screen  here was  validated  by  confirming  the  posttranscriptional  knockdown  of 
selected  genes  and  its  consequence  on  vector  transduction  efficiency  by  reverse 
transcription  quantitative  PCR  (RT­qPCR)  and  flow  cytometry.  Results  showed  that 









2.1.  Targeted  RNAi  screen  identifies  cellular  proteins  differentially  affecting  single­
stranded and double­stranded AAV vector transduction 
















































































vector  transduction  (transduction  rate  increased upon siRNA knockdown) are at  the  top of 
the list, proteins that have a positive effect on vector transduction (transduction rate reduced 
upon  knockdown)  are  listed  at  the  bottom.  Some  cellular  proteins  were  found  to  inhibit 
transduction, e.g. MRE11, NBN, RAD50, MSH3, PCNA, others, such as EEF1A1 were found 
to enhance transduction by both ss and sc AAV2 vectors. Yet other proteins were observed 
to  enhance  or  inhibit  transduction  by  one  but  not  the  other  vector;  for  example,  the 
knockdown of RFC2 inhibited the  transduction by the ss AAV2 vector but had no effect on 
that  of  the  sc  AAV2  vector.  An  interesting  group  of  proteins  includes  RPA1,  MSH2,  and 
MSH6, where siRNA knockdown led to opposite effects  for ss and sc AAV2 vectors. For a 
selected  set  of  proteins,  including  MSH2,  MSH3,  MSH6,  RPA1,  and  RFC2,  the  post­




The  influence of RPA1 on  transduction by ss and sc AAV vectors was  further  investigated 
because  it  showed  the most  differential  effect  in  the  RNAi  screen. We  analyzed  also  the 
effect of RPA2 on AAV transduction. Cells were reverse transfected with siRNA, inoculated 
48h  later  with  rAAVGFPNeo  or  scAAVGFP,  and  analyzed  at  24h  after  infection  by  flow 
cytometry  to  determine  the  percentage  and  the  mean  fluorescence  intensities  of  EGFP­





































































To  validate  the  RPA1  and  RPA2  effects,  we  first  established  an  assay  that  allowed  to 
specifically knock­down endogenous RPA1 and RPA2 and complement  it with exogenous, 
plasmid encoded protein.  In particular, we transfected cells  first with siRNAs against  the 5' 
untranslated region (utr) of  the endogenous RPA1 or RPA2 transcripts and, 24h  later, with 
expression plasmids encoding RPA1 or RPA2 cDNAs lacking the 5'utr (Fig. 4). At 24h after 
plasmid  transfection,  we  performed  RT­qPCR  with  primers  specific  for  the  coding 
sequences, which detect both endogenous and exogenous RPA1 and RPA2 transcripts, or 
primers specific  for  the 5'utr  regions, which detect only  the endogenous transcripts. Fig 4A 
shows  that  the  relative  RPA1  mRNA  levels  of  cells  treated  with  the  5'utr­specific  siRNA 
significantly  increased  upon  transfection  of  the  RPA1  encoding  plasmid  when  using  the 
coding  sequence­specific  primers  (graph  on  left)  but  not  when  using  the  5'utr­specific 
primers (graph on right). This demonstrates that endogenous RPA1 is indeed knocked­down 
and  that  the  increased  RPA1  mRNA  levels  detected  with  the  coding  sequence­specific 




later with rAAVGFPNeo or scAAVGFP. At 24h after  infection,  the cells were processed  for 
RT­qPCR to detect AAV vector­mediated EGFP expression (Fig. 5, A and B) or assessed by 
fluorescence  microscopy  (Fig.  5C).  The  increased  rAAVGFPNeo­mediated  EGFP 
expression levels observed upon knockdown of endogenous RPA1 or RPA2 were reversed 
to control levels when exogenous RPA1 or RPA2 was provided (Fig 5, A and C). Inversely, 









































































We next designed an assay  that allowed  the direct monitoring of  the differential  effects of 





can  be  summarized  as  follows:  The  RFP/CFP  (ssAAV/scAAV)  ratios  of  the  mean 








wtHSV­1  as  the  helper  virus.  At  24h  after  infection,  cells  were  processed  for  qPCR  to 








AAV  vectors  are  extensively  used  in  gene  therapy  applications  (Keeler  et  al.,  2017). 
Nevertheless,  a  better  understanding  of  their mechanisms  of  transduction  is  necessary  to 
enhance  their  applicability.  In  this  work  we  used  a  limited  RNAi  screening  strategy  to 




































































efficiency  of  ss  and  ds  (sc),  EGFP­encoding  AAV  vectors  on  a  single  cell  level.  For 
validation of the RNAi screen, the knockdown of selected genes as well as the effect on the 
transduction  efficiency was  determined  by RT­qPCR  and  flow  cytometry. We  found many 
cellular  proteins,  including  MRE11,  RAD50,  PCNA,  PRKDC  (DNA­PKcs),  MSH3,  and 
SMC1A with a negative effect on the transduction efficiency of both ss and sc AAV vectors. 
MRE11,  Rad50  and  NBS1  together  form  the  MRN  complex  which  has  previously  been 
shown to  inhibit  the transduction efficiency of AAV vectors (Cervelli et al., 2008; Lentz and 
Samulski,  2015;  Schwartz  et  al.,  2007).  Inhibition  of  gene  expression  was  observed  with 
both  ss  and  sc  AAV  vectors  and  was  described  to  depend  on  the  physical  interaction 
between the MRN complex and the vector genomes rather than on the nuclease activity of 
MRE11 (Lentz and Samulski, 2015).  
We  also  found  proteins,  such  as  the  eukaryotic  translation  elongation  factor  1  alpha  1 
(EEF1A1), which appear to enhance the transduction efficiencies of ss and sc AAV vectors. 
Other proteins had an apparent effect only on either ss or sc AAV vectors. For example, the 
knockdown  of  replication  factor  C  subunit  2  (RFC2)  and  heterogeneous  nuclear 
ribonucleoprotein  D0  (HNRNPD)  specifically  augmented  the  transduction  efficiency  of  ss 
AAV vectors. 
Of  all  the  proteins  investigated,  RPA1  showed  the  strongest  differential  effects  on  the 
transduction efficiency of ss and sc AAV vectors. While the knockdown of RPA1 lead to the 
largest increase in the transduction efficiency of the ss AAV vector, that of the sc AAV vector 
was  strongly  reduced.  The  same  effect  was  observed  also  when  treating  the  cells  with 
siRNAs specific  for RPA2 and was reversed upon delivery of plasmid encoded exogenous 
RPA1 or RPA2. 
RPA1,  RPA2  and  RPA3  together  form  a  heterotrimer  which  binds  to  ss  DNA  and  plays 
essential  roles  in  genome processing and maintenance  (for a  review see:  (Fanning et  al., 
2006;  Liu  and  Huang,  2016)).  DNA  binding  is  mediated mainly  by  RPA1,  which  contains 
three of the four ssDNA binding domains (DBD­A, ­B, ­C) (Brill and Bastin­Shanower, 1998; 




































































nevertheless  depend  on  RPA1  for  efficient  ssDNA  binding  (Bochkareva  et  al.,  1998).  As 
RPA has an approximately 1000­fold higher affinity  for ssDNA  than  for dsDNA (Kim et al., 
1994)  and  directly  binds  to  ssDNA  (Kenny  et  al.,  1990),  the  differential  effect  on  the 
transduction efficiency of  ss and sc AAV vectors  is not  surprising. Moreover,  as RPA  is a 
protein complex,  it was expected that  the knock­down of either component RPA1 or RPA2 
can affect the transduction efficiencies of the two different vectors.  
More  surprising  was  the  observation  that  only  RPA2  enhanced  HSV­1  mediated  AAV2 
replication  while  RPA1  had  no  significant  positive  or  negative  effect  on  virus  replication. 
Previous  studies  on  the  role  of  RPA  in  AAV2  replication  showed  contrasting  results.  For 
example, using a crude cytoplasmic extract of AdV­infected cells, Ni et al., (Ni et al., 1998) 




crude  cell  extracts  that  contained  RFC  and  PCNA  but  not  RPA  can  support  AAV2  DNA 
replication.  The  minimal  set  of  cellular  proteins  required  for  the  reconstitution  of  efficient 
AAV2 DNA  replication  in  vitro was  subsequently  found  to  include  polymerase  delta, RFC, 




Dany  et  al.,  2009; Weindler  and Heilbronn,  1991),  can  complement  its  activity. While  our 










































































complete  replication process, as a monoclonal antibody directed against RPA2  resulted  in 
the  inhibition  of  SV40  DNA  replication  (Erdile  et  al.,  1991a;  Erdile  et  al.,  1991b).  This 




as  AAV  Rep  or  HSV­1  ICP8,  and  cellular  factors,  e.g.  RFC  or  components  of  the  MRN 
complex.  These  interacting  proteins  are  involved  in  DNA  processing.  A  large  number  of 
different proteins bind  to RPA (for  reviews see:  (Fanning et al., 2006;  Iftode et al., 1999)). 
While  some of  these proteins,  such as RAD9 or RAD52,  can bind  to  both  subunits,  other 
proteins  bind  specifically  to  either  RPA1  (e.g.  P53,  RFC,  RAD51)  or  RPA2  (activation 
induced  cytidine  deaminase,  Uracil­DNA  glycosylase).  These  different  activities  could  be 
regulated by DNA protein kinase or the ataxia telangiectasia­mutated (ATM) protein kinase, 
both of which target RPA (Iftode et al., 1999). 
The mechanisms responsible  for  the observed differential  requirement of RPA1 and RPA2 
for AAV2 replication as well as for the apparent enhancement of the transduction efficiency 
of  sc AAV vectors and  inhibition of  that of  ss AAV vectors  remain  to be  investigated. The 
present  study  nevertheless  provides  a  useful  strategy  to  screen  the  role  of  selected 
functional groups of proteins in specific phases of the viral life cycle and to validate the data 
by  reversing  the  effects  through  ectopic  expression  of  the  corresponding  genes.  In 
particular, the observed differential effects of specific cellular proteins on vector transduction, 
depending  on  the  conformation  of  the  vector  genome,  may  allow  to  draw  conclusions 







































































4.1. Cells.    HeLa  cells  (ATCC),  293T  cells  (kindly  provided  by  J. Neidhardt, University  of 
Zürich, Switzerland), and Vero cells (ECACC) were maintained in growth medium containing 






4.2. Viruses  and plasmids.   HSV­1  strain F  (kindly  provided  by B. Roizman, Marjorie B. 
Kovler Viral Oncology Laboratories, University of Chicago, Chicago, USA) was grown and 
titrated on Vero cells. Wild­type (wt) AAV2 was grown and  titrated as described previously 
(Lux  et  al.,  2005).  Plasmids  pAAVGFPneo  and  pscAAVGFP  containing  the  recombinant 
(r)AAVGFPNeo  and  self­complementary  (sc)AAVGFP  vectors  were  kindly  provided  by M. 
Linden  (King's  College  London  School  of  Medicine,  London,  UK)  and  J.  Neidhardt 
(University of Zürich, Switzerland), respectively. 
rAAVRFPNeo  was  constructed  by  replacing  the  EGFP  coding  sequence  in  plasmid 
pAAVGFPneo  with  the  mRFP  coding  sequence  as  follows:  pcDNA­mRFP1­N  (kindly 
provided  by  M.  Gastadelli,  Institute  of  Molecular  Life  Sciences,  University  of  Zurich, 
Switzerland) was  digested with BamHI  and NotI,  and  the  711  bp  fragment  containing  the 
mRFP  coding  sequence  was  ligated  with  the  6491  bp  BamHI­NotI  fragment  of 
pAAVGFPneo.  The  resulting  plasmid  was  termed  prAAVRFPNeo.  scAAVCFP  was 
constructed by replacing the EGFP coding sequence in plasmid pscAAVGFP with the ECFP 
coding sequence as follows: a DNA fragment containing the CMV enhancer/promoter­ECFP 
coding  sequence  was  amplified  by  PCR  from  plasmid  pCMVeCFP­PolyA  (unpublished 
material)  using  forward  (5'­AAGATATCACTAGTTAGTTATTAATAGTAATCAATTACG­3') 






































































was termed pscAAVCFP. Transgene expression from all AAV vectors used  in  this study  is 
controlled  by  the  human  cytomegalovirus  IE1  enhancer/promoter  (CMV  promoter).  AAV 
vector stocks were produced by transient transfection of 293T cells with pDG (Grimm et al., 
1998) and either pAAVGFPNeo, pAAVRFPNeo, pscAAVGFP or pscAAVCFP. Virus stocks 
were  purified  by  Iodixanol  gradient,  and  titers  were  determined  as  described  elsewhere 
(Grieger et al., 2006).  







Fischer  Scientific,  Switzerland;  see  Supplementary  Table  1).  All  experiments  were 
conducted  in  96­well  tissue  culture  plates.  For  screening,  the  plates  contained  one  of  the 





14 μl OptiMEM (final concentration 10nM). After  incubation  for 20min at  room  temperature 
(RT), 2.5x103 HeLa cells in 80 μl DMEM/10% FBS were added per well. After 48h incubation 
at 37°C,  the cells were  infected with either  rAAVGFPNeo  (MOI 3000) or scAAVGFP  (MOI 






































































Numbers  of  cell  nuclei  and  numbers  of  EGFP­positive  cells  were  recorded  by  using  an 




(Semrock).  Images  were  further  analyzed  with  CellProfiler  software  (BROAD  Institute, 
Cambridge,  MA,  USA;  (Carpenter  et  al.,  2006))  and  KNIME  (KNIME.COM  AG,  Zurich 
Switzerland).  Transduction  rates  from  triplicate  experiments  xnk1,2,3  (n    {genes},  k   
{siRNAs  1,  2,  3})  and  controls  (xscr1k1,2,3  ,  xscr2k1,2,3  and  xno_siRNAk1,2,3)  were  calculated  by 
dividing the number of EGFP­positive cells by the number of cell nuclei. The mean xnk, xscr1k, 
xscr2k and xno_siRNAk of each triplicate was calculated. The control transduction rate xcontrolk  was 







in  300 μl  DMEM/10%  were  added  per  well.  For  some  experiments,  the  cultures  were 
transfected at 24h after siRNA  transfection with empty vector DNA  (pUC19) or expression 
plasmids  encoding  RPA1  or  RPA2  (50  ng  DNA,  5  μl  Lipofectamine  2000;  Invitrogen) 
according  to  the  manufacturer's  protocol.  At  48h  after  siRNA  transfection,  the  cells  were 
infected with rAAV vectors, scAAV vectors, or wtAAV2 (MOI 3000) alone or  in presence of 
wtHSV­1  (MOI  3)  as  described  above  and  in  the  figure  legends.  At  72h  after  siRNA 










































































the  AAV2  rep78­coding  sequence  (fw:  5’­ATTGACGGGAACTCAACGAC­3’;  rev:  5’­
CCTCAACCACGGATCCTTT­3’;  TaqMan  probe:  5’­CATGATCCAGACGGCGGGTGA­3’), 
and the following conditions: 2 min 50oC, 15 min 95oC, 40x (15 sec 94oC, 30 sec 56oC, 15 
sec 72oC).  
For  gene  expression  analysis,  the  cells  were  lysed with  TRIZOL  (Life  Technologies),  and 
total RNA was  isolated and  treated with DNAse using Direct­zol RNA kit  (Zymo Research, 
Irvine,  CA,  USA),  and  reverse­transcribed  with  random  hexamer  primers  (Promega, 
Madison, WI, USA) and  the Reverse Transcription System kit  from Promega. Quantitative 
PCR was performed using SYBR Green (Life Technologies) in a CFX96 Real­Time system 























































































Cells  were  trypsinized  and  washed  once  with  PBS.  Flow  cytometry  was  performed  on  a 





Extrachromosomal  DNA  was  extracted  according  to  the  protocol  described  by  Hirt  (Hirt, 
1969). The DNA was separated on 1% agarose gels and  transferred  to nylon membranes 
(Amersham  Hybond­N+  RPN119B).  Hybridization  with  a  digoxigenin  (DIG)­labeled  probe 
specific  for  AAV2  rep78,  detection  by  an  anti­DIG  antibody  conjugated  with  alkaline 
phosphatase,  and  activation  with  the  chemiluminescence  substrate  CDP  Star  was 
performed  according  to  the  manufacturer's  protocol  (Roche,  Mannheim,  Germany).  The 
DIG­labeled probe was produced with the PCR DIG probe synthesis kit (Roche) as follows: 














































































We would  like  to  thank J. Neidhardt, B. Roizman, M. Linden, M. Gastadelli, M. Wold, and 
J.A.  Borowiec  for  providing  reagents,  A.  Man  and  E. Yàngüez  López­Cano  for  technical 
help, and S. Stertz, N. Wolfrum, M. Seyffert, S. Sutter and A. Meier for critical discussions.  






Salvetti,  A.,  2009.  Definition  of  herpes  simplex  virus  type  1  helper  activities  for  adeno­
associated virus early replication events. PLoS Pathogens 5, e1000340. 
 
Bochkareva, E.,  Frappier,  L., Edwards, A.M., Bochkarev, A.,  1998. The RPA32  subunit  of 




























































































Collaco,  R.F.,  Kalman­Maltese,  V.,  Smith,  A.D.,  Dignam,  J.D.,  Trempe,  J.P.,  2003.  A 
biochemical  characterization  of  the  adeno­associated  virus  Rep40  helicase.  J  Biol  Chem 
278, 34011­34017. 
 
Erdile,  L.F.,  Collins,  K.L.,  Russo,  A.,  Simancek,  P.,  Small,  D.,  Umbricht,  C.,  Virshup,  D., 
Cheng,  L.,  Randall,  S.,  Weinberg,  D.,  et  al.,  1991a.  Initiation  of  SV40  DNA  replication: 
mechanism and control. Cold Spring Harb Symp Quant Biol 56, 303­313. 
 
Erdile,  L.F.,  Heyer,  W.D.,  Kolodner,  R.,  Kelly,  T.J.,  1991b.  Characterization  of  a  cDNA 

























































































C.,  2005.  Four­dimensional  visualization  of  the  simultaneous  activity  of  alternative  adeno­
associated virus replication origins. J. Virol. 79, 12218­12230. 
 
Glauser,  D.L.,  Seyffert,  M.,  Strasser,  R.,  Franchini,  M.,  Laimbacher,  A.S.,  Dresch,  C., 
Oliveira,  A.P.d.,  Vogel,  R.,  Büning,  H.,  Salvetti,  A.,  Ackermann,  M.,  Fraefel,  C.,  2010. 




Glauser,  D.L.,  Strasser,  R.,  Laimbacher,  A.S.,  Saydam,  O.,  Clément,  N.,  Linden,  R.M., 
Ackermann, M., Fraefel, C., 2007. Live covisualization of competing adeno­associated virus 




















































































Hoggan, M.D.,  Blacklow, N.R., Rowe, W.P.,  1966. Studies  of  small DNA  viruses  found  in 























































































Kim,  C.,  Paulus,  B.F., Wold, M.S.,  1994.  Interactions  of  human  replication  protein  A  with 
oligonucleotides. Biochemistry 33, 14197­14206. 
 








of  a  region­specific  viral  DNA  integration  site  on  chromosome  19q13­qter.  Genomics  10, 
831­834. 
 


















































































D.M.,  Finke,  S.,  Hallek,  M.,  Buning,  H.,  2005.  Green  fluorescent  protein­tagged  adeno­
associated  virus  particles  allow  the  study  of  cytosolic  and  nuclear  trafficking.  J.  Virol.  79, 
11776­11787. 
 






Nash,  K.,  Chen,  W.,  Muzyczka,  N.,  2008.  Complete  in  vitro  reconstitution  of  adeno­



















































































Salvetti,  A.,  2012.  Factors  influencing  helper­independent  adeno­associated  virus 
replication. Virology 432, 1­9. 
 




Ramo,  P.,  Drewek,  A.,  Arrieumerlou,  C.,  Beerenwinkel,  N.,  Ben­Tekaya,  H.,  Cardel,  B., 
Casanova,  A.,  Conde­Alvarez,  R.,  Cossart,  P.,  Csucs,  G.,  Eicher,  S.,  Emmenlauer,  M., 
Greber, U., Hardt, W.D., Helenius, A., Kasper, C., Kaufmann, A., Kreibich, S., Kuhbacher, 
A.,  Kunszt,  P.,  Low,  S.H.,  Mercer,  J.,  Mudrak,  D.,  Muntwiler,  S.,  Pelkmans,  L.,  Pizarro­
Cerda, J., Podvinec, M., Pujadas, E., Rinn, B., Rouilly, V., Schmich, F., Siebourg­Polster, J., 
Snijder, B., Stebler, M., Studer, G., Szczurek, E., Truttmann, M., von Mering, C., Vonderheit, 
A.,  Yakimovich,  A.,  Buhlmann,  P.,  Dehio,  C.,  2014.  Simultaneous  analysis  of  large­scale 
RNAi screens for pathogen entry. BMC Genomics 15, 1162. 
 
Roulin,  P.S.,  Lotzerich,  M.,  Torta,  F.,  Tanner,  L.B.,  van  Kuppeveld,  F.J.,  Wenk,  M.R., 
Greber, U.F., 2014. Rhinovirus uses a phosphatidylinositol 4­phosphate/cholesterol counter­















































































D.,  Balistreri,  G.,  Schelhaas,  M.,  De  Haan,  C.A.,  Marjomaki,  V.,  Hyypia,  T.,  Rottier,  P.J., 






























































































2  modulates  the  host  DNA  damage  response  induced  by  herpes  simplex  virus  1  during 
coinfection. J Virol 86, 143­155. 
 




Ward,  P.,  Dean,  F.B.,  O'Donnell,  M.E.,  Berns,  K.I.,  1998.  Role  of  the  adenovirus  DNA­
binding protein in in vitro adeno­associated virus DNA replication. J. Virol. 72, 420­427. 
 
Weindler,  F.W.,  Heilbronn,  R.,  1991.  A  subset  of  herpes  simplex  virus  replication  genes 
















































































Wu,  J.,  Davis,  M.D.,  Owens,  R.A.,  1999.  Factors  affecting  the  terminal  resolution  site 




U.F.,  2015.  Plaque2.0­A  High­Throughput  Analysis  Framework  to  Score  Virus­Cell 
Transmission and Clonal Cell Expansion. PLoS One 10, e0138760. 
 




Yoon­Robarts, M.,  Linden,  R.M.,  2003.  Identification  of  active  site  residues  of  the  adeno­
associated virus type 2 Rep endonuclease. Journal of Biological Chemistry 278, 4912­4918. 














































































the  transduction  efficiencies  of  single­stranded  (ss)  and  double­stranded  (ds)  self­






(A) Primary  screening workflow.    (B) Representative high  throughput widefield microscopy 




and  right  is  based  on  the median  values  of  the  relative  transduction  rates  from  the  three 





PCR (RT­qPCR). HeLa cells were  treated with siRNAs  targeting  individual genes selected 
from  the  primary  screen  (MSH2,  MSH3,  MSH6,  RPA1,  RFC2;  pools  of  three  different 
siRNAs) or scrambled siRNA (scr2). After 48h, the cells were infected with (A) rAAVGFPNeo 
(MOI 3000) or (B) scAAVGFP (MOI 3000). At 24h after infection, total RNA was isolated and 





































































as  means  from  triplicate  experiments.  Error  bars  show  standard  deviations  of  the  mean. 
*P<0.05, ***P<0.001. 
 















primers,  cs;  left  panels)  or  endogenous  (5'utr  primers,  right  panel)  RPA  1  and  RPA2. 





and  fluorescence microscopy.  HeLa  cells  were  treated  with  scrambled  siRNA  (scr2)  or 
siRNAs targeting the 5'utr of either RPA1 or RPA2. After 24h, the cells were transfected with 
an  empty  vector  (ev)  or  plasmids  encoding  either RPA1  or RPA2  and,  24h  later,  infected 





































































and GAPDH  (internal  control). EGFP/GAPDH mRNA  levels  of  each  sample  normalized  to 
scr2  siRNA  is  shown  as  means  from  triplicate  experiments.  Error  bars  show  standard 
deviations  of  the  mean.  **P<0.01,  ***P<0.001.  (C)  Representative  photomicrographs  of 
rAAVGFPNeo  infected cells  transfected with siRNAs and expression plasmid as  indicated. 
Scale bar = 100 μm. 
 
Fig.  6.  Exogenous  RPA1  and  RPA2  block  transduction  by  ssAAV  vectors:  flow 
cytometry. HeLa  cells were  treated with  scrambled  siRNA  (scr2)  or  siRNAs  targeting  the 
5'utr of either RPA1 or RPA2. After 24h, the cells were transfected with plasmids encoding 
either  RPA1  or  RPA2  or  an  empty  vector  (ev)  and,  24h  later,  infected  with  either  (A) 
rAAVGFPNeo  (MOI  3000)  or  (B)  scAAVGFP  (MOI  3000).  At  24h  after  infection,  the  cells 
were  harvested  and  subjected  to  flow  cytometry  to  determine  the  percentage  of  EGFP 
positive  cells  (left  panels)  and mean  fluorescence  intensities  (right  panels).  40’000 events 
(cells)  per  sample  were  counted.  The  data  represent  mean  values  from  triplicate 
experiments. Error bars show standard deviations of the mean. **P<0.01, ***P<0.001. 
 
Fig.  7.  Effects  of  RPA1  and  RPA2  on  the  transduction  efficiencies  of  ssAAV  and 
scAAV vectors in co­infected cells. HeLa cells were treated with scrambled siRNA (scr2) 
or siRNAs targeting the 5'utr of either RPA1 or RPA2. After 24h, the cells were transfected 














































































and,  24h  later,  infected  with  wtAAV2  alone  (MOI  3000)  or  co­infected  with  wtAAV2  (MOI 
3000) and wtHSV­1 (MOI 3). At 24h after infection, total DNA was isolated and subjected to 
quantitative PCR with primers specific  for AAV2 rep78 or TERT (endogenous control). The 
graph  in  (A)  shows  relative  AAV2  DNA/TERT  DNA  levels  as  means  from  triplicate 
experiments, normalized to co­infected cells transfected with scr2 siRNA and empty vector. 




Supplementary  Fig.  1.  Efficiency  of  siRNA  knockdown.  HeLa  cells  were  treated  with 
siRNAs targeting individual genes selected from the primary screen (MSH2, MSH3, MSH6, 
RPA1, RFC2;  three different siRNAs each) or scrambled siRNA (scr2). After 48h,  the cells 
were  lysed with TRIZOL  (Life Technologies),  and  total RNA was  isolated and  treated with 
DNAse using Direct­zol RNA kit (Zymo Research, Irvine, CA, USA), and reverse­transcribed 
using random primers (Promega, Madison, WI, USA) and the Reverse Transcription System 
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Click here to download Figure: Franzoso et al. Fig. 2.pdf
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GeneSymbol Target sequence 1 Target sequence 2 Target sequence 3 Supplier 
 
ATM UAACAAACAGGUGAUAUAU UUGGUUUUAUGACAAUUGC UUUUCAAACAGGUAACAGC Ambion 
ATR UCAGUAUCCAUUUCUACAA UUGACUUAAAAAUCGGCUC UAAAUUUUGCAUACUCAUC Ambion 
ABCE1 AUCGGUCACAAAUUGUGGG UUUCGUUCUUUUAGGUGGG UUCGGUCCAAAAUAGAUCC Ambion 
ACAD9 UGAUCCAUCAGAAUCAACG UCUCUUUCUACUAUGAAUG UCGCUUCUCAAGGAUCUGC Ambion 
ANXA5 UCCUGAUAUAGUCAUGUAC UUAGUUCUGAUUUCAGGUC AACAGAUCAAUCUCACUCC Ambion 
ARL8B UAUCUAGAAGAUUAUGUAG UAUCUUCACUGAAUUGACC AUAGCAUUGACUCCUCUGC Ambion 
ATP5O UGUCAUUUAGGCUUUUCAC AAUGGUCUGACCACAGAGG UGACGGAUCAGUCUUAGCC Ambion 
CHEK2 UAGGAUAAACUGACUGAUC UUCUGUCGUAAAACGUGCC UUCUGCUUAGUGACAGUGC Ambion 
CMC1 UUAUAGUAAGCAGUUAGAC UUACUACCAUAAGAACUCC UUAGACAUUCUUUCAAUGC Ambion 
DDX17 AUAGCUUGCAGAGUCUCUC AUCGGUUUCACUACGAUCC UAACCUAUCAUAUUGGUAG Ambion 
EEF1A1 UUCACUCAAAGCUUCAUGG AAUGUAAGUGCUGACUUCC UUUCGACAGAUUUUACUUC Ambion 
FLII UGAGGUCCAGGUAUAGUAG UUUCGGGACAGGUUCAGAG UCGUUGAUAACCUGCUUGC Ambion 
GMNN UCUUGGGACAGAACUAUUC AGAUGUUAAGUGGUCAUUC UAAGAUCAAAUGACUCCUG Ambion 
H2AFX UUACCAAGUGCUUCGUCCC UGUGCUGGUAUCUAGGUGC UUGGAUUGCCGAGUUGAGU Ambion 
HIST1H1E UUAGUAAUGAGCUCGGACA UUUGGUUUAGCCGCCUUGG AGCUUUAGUAAUGAGCUCG Ambion 
HIST1H1A UUAGAUGCACCCGUUGCCU UUGGGUUUUACAGCCUUAG UUGCCUUAGUUUUUGUAGC Ambion 
HNRNPA3 UCUAUGGUUUCAAUCUUGC UCAUCUGUAGUUUCAAAGC UACACGCCCAUCAACCUUG Ambion 
HNRNPAB UCUUUGAACAGGAUAAACC UUUGUUCAACUUUGGAUCC UUUCUUCACCGGGUCCUUC Ambion 
HNRNPC UAUCAUAAUAGUCCCGUUG UGACUUAUCAUUCUUCAUC UUCUUGACCACAAGAGUGU Ambion 
HNRNPD UAUCUACACUCUCCGAUUC AAGGUAAUAAAGCAGAACC UUAGGAUCAAUCACCUUCC Ambion 
HNRNPH1 AUUUGGACCAGUAUGCUUC UCUGCUUCACCAGUUACUC AUCUAUCUGACCCAAAUCC Ambion 
HNRNPM UGCUUUGCAAUGAUCUCUC AAAGUAACAGUGCCUAUUC UGGUCUAUCAAAUAGCAGC Ambion 
HSPA8 UAUGCUUGCGCUUAAACUC UUUUGUCUAAGCCGUAAGC UCAUUCACCACCAUAAAGG Ambion 
KRT13 UUAAGGCCUACGGACAUCA UUGGUAGACACCUCCUUGU UCCGUGAUCUCUGUCUUGC Ambion 
LMNA UCCAGUUUGCGCUUUUUGG UAUCAGGUCACCCUCCUUC UCAGGGUGAACUUUGGUGG Ambion 
LMNB1 UUUGCGAAACUCCAAGUCC AAGGCUCUGACAACGAUUC UUCUGGUCUCGUUAAUCUC Ambion 
LMNB2 UCACGCAUCACCGAGGACU AUCCUUGUCCGAGUUGUUC UACUUGGGCGUGAACUUGU Ambion 
LMO7 AACGUGAUAUCAGAGGAGC UUUGUUGCCUCUCCAAUUC UUCGAUACGACAUAUCAUC Ambion 
MCM7 UCUUUAUUUACCACUUCCC UUAUUUACCACUUCCCUCU UUGGGUUUGACUUCAGAGA Ambion 
MPRIP UUCUGAUUCUGCUUGUUGG UACUCUGUGACAUCGUAAC AAAGGAUGAAGAACCGUCG Ambion 
MRE11A AACCGGACUAAUGUCUAUC UUAGUAGUGACAUUUCGGG UAUAGUCCACUCGCAGUCG Ambion 
MSH2 UUACACGAAAGUAAUAUCC UAAGAUCUGGGAAUCGACG UAUCAUAUCCUUGCGAUUC Ambion 
MSH3 UUCCGAUACAGCAUCAAGC UGUAUUGUAAUUCUAGCGG UCCGAUACAGCAUCAAGCC Ambion 
MSH6 UCCAGUAUCGUUUACAGCC UCUGUUACGUAAGUUGUGC UUUCGAGCAACUUUGACAG Ambion 
MYH10 ACAACGAACAAAGUUAGGG UUGACGAACAGCACGAGAC AACGGUACGAAACAUGCCC Ambion 
MYL12B UAUGCAUCAGUGGGAUUCU UACAUCAAAAAGAAGAGGC AGUCUGAUUAUACAAGUGC Ambion 
MYLK2 UGAUCUUCACCAAAUGCCC UUGGUCAUAAUUCACCACC UGUCUUAUCGGAGAUUUGG Ambion 
NBN AAUAGGUCUAAGACCUUGC UACCAUACUUAGAAUUAUC UGACCAUAGUGAGUCUUCC Ambion 
NUP153 AUCGGUAGAGAGAUUUUCG AAUCUAUCUUCGGCGAUGC UAUUUCGUAGUUUAGACUG Ambion 
PARP1 UUUGUUGCUACCGAUCACC UCAUAGUUGACAUCGAUGG UCUUCGGUUAUGAAGCUGC Ambion 
PCNA UGAGAUCUCGGCAUAUACG UUGCAGAAAAUUUCACUCC UUAGUGUAAUGAUAUCUUC Ambion 
PHB AUUGGUUUCUGUACCCACG UCAUAGUCCUCUCCGAUGC UUGAGGAUCUCAGUUGUGA Ambion 
PHGDH UAUUAGACGGUUAUUGCUG UGAGCUCCAAGGUUAGAAG UUUAUUAGACGGUUAUUGC Ambion 
POLD1 UCCAUGAUACGGAUGAAGG UUGGUUUUCUCGAUCAUCU AAUGUUUGUACCUUGAGGG Ambion 
PRKDC UGUUGUAGCACUCCAACGC AGUUCACCCAGAAAAGCGC AAGGCUAUAAAGUCGCUUG Ambion 
RAD50 UUCACGAUGACAGUCUACC UUCGAUCUAAGUCUAUUCC UUCGUAACUGGACAACUGC Ambion 
RBM14 AACUGUUUCAUGACGGCGC UUCUUUGCCGUUGAGCUGC UAUAGGAGCCCGAAUAGCG Ambion 
RFC2 UGGUUUUAGAGUAGAUUUC UUACAAGCAAGGGCGAAGC UUCUCGAUAACAUUCAUCA Ambion 
RPA1 UUCGCAAUGAUAGUGCUUG UUUACUGACAGGAUCAUGC UUUCGAGAAAUAAUACACC Ambion 
RUVBL2 UGUUACAUCACGGAUCUCC UGCUGGUCGAUCAAUCUGG UUCUGUACCCUUGCGUUUC Ambion 
SFPQ AGAUCUUCCACGAUCAUCC UAUUCGUACUCAAACGUGC UCCACUAUUACAACAGCCC Ambion 
SLC25A6 UACGUGGUUCUCUUGGUUC UAUUGUUUUGCAGCAGGAG AAAGUACCUCCAGAACUGC Ambion 
SMC1A AAACGAGGAAGUUACGAGC UGUACUCAGAAGAACCUCC UCGAAGGUCAGGACUUUGC Ambion 
SPTAN1 UGUCCUUCAACCGUGACUC UUAGCUUGGUUGCAAAUUC UAAUCGCUUUGUCAAAGUC Ambion 
SSBP1 UUUUUAUCCAUGUAUUCAC UUAUCAGCUAUGAUUGUUG UCAGCUAUGAUUGUUGUUG Ambion 
TP53 UUCCGUCCCAGUAGAUUAC UACUCCACACGCAAAUUUC UUAGGUACUAAGGUUCACC Ambion 
TMOD3 UGUCUUUAUGCUCCAAUGC UCUUGGUCAACACCAUUAC UAUUCGUUAUCAAAUUGUG Ambion 
TUBB4B UUAUCAAUGCAGUAGGUCU UUCGUUAUCAAUGCAGUAG UGACCGAAAACGAAGUUGU Ambion 
TUFM ACAUGAGCCGCAUUGAUGG UAUUCUUAACAUAAUCUGC UAACAUAAUCUGCAUGACC Ambion 
VIM UUGCGUUCAAGGUCAAGAC UUUUGAGUGGGUAUCAACC AUCCAGAUUAGUUUCCCUC Ambion 
XRCC5 UUCUAUACCAGGAAUGGAG UUUGUUGUCACCUCAGCGG UCCAUGCUCACGAUUAGUG Ambion 
XRCC6 UGUCAACUCAUCUUCACUC UUGAGCUUCAGCUUUAACC UGUAGAACAAGGAUAUGUC Ambion 
KIF11      CCAUCAACACUGGUAAGAA Ambion 
scr1      UCGUAAGUAAGCGCAACCC                                                    Ambion 
scr2      UAACGACGCGACGACGUAA                                                    Ambion 
 
RPA1utr GGAAUUAUGUCGUAAGUCAUU   Microsynth 
RPA1cs CAAGCACUAUCAUUGCGAA   Microsynth 
RPA2utr AACCUAGUUUCACAAUCUGUUUU   Microsynth 
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6. Discussion and Perspectives 
 
The data on cell cycle dependent AAV2 gene expression/replication as well as effects of 
specific cellular proteins on the transduction efficiencies of AAV vectors are discussed 
in the respective manuscripts (chapters 5.1. and 5.2.). Here an overview of the recent 
strategies to overcome possible obstacles in order to create vectors with improved AAV-
mediated gene delivery and the implications of this work for AAV2 research, AAV2 
mediated gene therapy, and vector production is presented. 
 
   6.1. AAV vectors for therapeutic gene delivery 
 
Increasing numbers of phase I-III clinical trials using AAV vectors with promising results 
appear to gradually remove the barriers for treating familial lipoprotein lipase LPL 
deficiency (first AAV1 vector encoding the gain-of-function LPL variant obtained market 
approval in EU in 2012) (93, 95),  various monogenic disorders and chronic conditions 
such as Leber’s congenital amaurosis type 2 (233), hemophilia B (89, 234, 235), 
nervous system, eye, muscle and heart diseases (91, 236, 237).  
Persistent gene expression, one of the great advantages of using AAV vectors, was 
demonstrated in vivo with most AAV vectors. For example, beta-galactosidase was 
expressed for more than one year and half after intramuscular injection (238), 
erythropoietin for six months after systemic injection (239) or other genes showed long-
term expression after injection into the eye, brain, spinal cord, muscle and liver (240–
242). However, the ultimate goal would be treatment of genetic diseases with a single 
application of AAV vectors that would last for life.  
One of the major rate-limiting steps for gene expression in vivo was demonstrated to be 
the second-strand synthesis (243). To overcome this limitation, McCarty et al (79, 244) 
created a ds vector termed self-complementary (sc) that has a greatly enhanced 
transduction efficiency. However, at the same time the transgene capacity is greatly 
reduced. 
At the moment more than 13 different AAV serotypes with various in vivo tissue 
tropisms are used for packaging rAAV cassettes. Improvement of infectivity in the target 
cells was achieved either by capsid modifications (inserts of amino acids (245) or 
creating capsid libraries (246)) or changing specific promoters (247) or introducing 
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  microRNA into the transgene cassette to inhibit gene expression in non-targeted organs 
(248). Other capsid engineering methods comprised also site-directed mutagenesis 
(249), creating capsid libraries, elaborating screening methods (250) or mutating 
tyrosine to phenylalanine to reduce risks of cytotoxic T lymphocyte immune responses 
(251). Empty AAV2 capsid particles with mutations targeting primary cell receptor 
binding showed also promising results (252).  
Another interesting approach was to change the tropism to and for target cells, as the 
liver is often the target destination, by incorporation of high-affinity ligands which restrict 
or redirect viral tropism (253). Moreover, an AAV2/AAV8 chimera (AAV2i8) showed an 
altered transduction profile as it selectively transduced cardiac and skeletal muscle 
while losing the liver tropism (254).  
 
   6.2. Cellular factors and AAV vector transduction 
 
Another important research strategy in AAV vectorology represents the investigation of 
possible pathways toward transgene expression and rAAV transduction mechanisms. 
Ss DNA vector genomes are assumed to be uncoated within the nucleus and form 
discrete foci that directly correlate to the transduction efficiency (255). 
It was demonstrated that Mre11, Nbs1, and ATM are required for efficient vector 
genome circularization in dividing cells, suggesting that recombination pathways 
occuring at the terminal repeats (TRs) are involved in AAV persistance (81). In 
nondividing skeletal muscle fibers, ATM and DNA-PKs were necessary for vector 
genome circularization, whereas Nbs1 was not required (194, 256). 
rAAV transduction can elicit a DNA damage response  that can greatly influence the 
transduction. Dividing cells deficient for ATM showed increased transduction due to 
enhancement of second-strand synthesis (85, 257). DNA synthesis inhibitors such as 
aphidicolin or hydroxyurea and topoisomerase inhibitors such as camptothecin or 
etoposide increased transduction in both dividing and nondividing fibroblast cultures 
(258) showing that treatments that affect DNA metabolism can influence AAV gene 
expression. Furthermore, when  ATM defective cells were treated with a genotoxic 
agent the increase in AAV transduction efficiency was limited (85), supporting the 
concept that ATM inhibits transduction at the genome level. Ku86 and Rad52 are also 
involved in this effect as Ku86 can inhibit further maturation of AAV DNA while Rad52 
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  leads to activation of AAV gene expression through activating the homologous 
recombination (HR) pathway (259). These findings further emphasize that  a profound 
understanding of the role of host factors involved in recombination mechanisms would 
allow to characterize a potential rAAV gene therapy genotoxicity (29).  
Interestingly, in vivo studies in mice demonstrated that downregulating of DNA repair 
proteins, in particular the MRN complex genes Mre11, Rad50, Nbs1 increased vector 
transduction (237, 261). The MRN complex has been shown to inhibit the transduction 
efficiency of ss and sc AAV vectors dependent on the physical interaction with the 
vector genome rather than the nuclease activity (86, 262).  
Our high-throughput siRNA screening approach identified positive and negative effects 
on ss and sc AAV vector transduction . We found cellular proteins such as Mre11, 
Rad50, PCNA, PRKDC, MSH3 and SMC1A with a negative effect on the transduction 
efficiency of both ss and ds AAV vectors. EEF1A1 appears to enhance transduction of 
ss and sc AAV vectors, whereas the knockdown of RFC2 and HNRNPD augmented the 
transduction of ss AAV vectors. Cellular DNA damage responses appear to be a strong 
determinant of AAV transduction, as shown also on a genome-wide scale in Mano et al 
(263).  
RPA1 showed the most differential effect on transduction of ss and ds and it was 
selected as our target gene. Similar results were obtained with RPA2. As RPA has an 
approximately 1000-fold higher affinity for ssDNA than for dsDNA (264), the differential 
effect was not surprising. However, the underlying molecular mechanism remains to be 
investigated. Two other RNAi screenings have been previously described aiming to 
identify cellular factors controlling AAV transduction. The screening of Wallen et al (24) 
in human aortic endothelial cells using the Druggable Genome Library of 5520 genes 
showed many off-target effects which makes difficult a solid comparison with our 
results. The genome-wide siRNA screening for 18120 gene targets reported by 
Giacca’s laboratory (263) identifying positive and negative regulators in ssAAV2 and 
scAAV2 transduction showed similar results with our study for the DNA damage 
proteins like MRN complex but also discovering differential effects of new genes like 
SETD8, CASP8AP2 or TROAP in both in vitro and in vivo assays in the hepatic tissue.  
Our study offers a new perspective when using RNAi strategy, with potential 
translational value and adds new knowledge that can further lead to possible tracking of 
new cellular pathways and improved AAV-based viral vectors for gene therapy.  
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     6.3. Cell cycle and AAV vector transduction 
 
The cell cycle appears to affect AAV vector transduction. Genotoxic stress that can 
provoke a cell cycle arrest resulted in increased transduction (265, 266). In absence of 
normal checkpoint functions, such as in p53-deficient cells or human embryonic stem 
cells, the AAV transduction results in cell death (168, 256). However, the mechanisms 
undelying these transduction effects are not well understood.  
One report on AAV transduction and cell cycle by Russell and coworkers (198) showed 
that cells in S-phase are transduced up to 200-fold more efficiently compared to non S-
phase cells. They concluded that, although S phase is preferentially transduced by AAV 
vectors, S phase is not absolutely required for transduction. At a mechanistic level, 
cellular DNA polymerases active in S phase could convert ss AAV vector genomes to 
transcriptionally active ds molecules (197, 198). Moreover, it was suggested that most 
transduction events were associated with vector integration and that integration is the 
rate-limiting step for transduction (198).  
Importantly, AAV transduction induces a cell cycle arrest at G1 and G2/M checkpoints in 
wt diploid cells (168, 267). In cells defective for specific cell cycle checkpoints, the 
transduction is initially increased, probably due to a faster entry into S phase (256, 268). 
In our first study we demonstrated that AAV2 transcription and replication was efficient 
in S/G2 and G1 cells when the template was a circular ds rather than a linear ss DNA, 
indicating that the S/G2 phase preference of ssAAV vectors is due to inefficient second-
strand synthesis in that cell cycle phase. Indeed, as opposed to the ss AAV vectors, 
infection of cells with scAAV2 vectors  resulted in a considerable proportion of AAV2 
transgene-positive G1 cells in absence of the helper virus. However, our high-
throughput multi-channel time-laps microscopy study showed that the majority of the 
scAAV2 transduced G1 cells originated from transduced S/G2 cells that progressed 
through mitosis. rAAV2 vectors can induce a cell cycle arrest more efficiently than 
scAAV2 vectors likely because of the ss versus ds nature of the genome. In presence of 
the helper virus, neither ss not ds vector transduced cells progressed through mitosis 
presumably because of an HSV-1 induced G2 arrest. These observations can be used 
in designing new vectors with a better transduction efficiency in slowly dividing cells, 
including hematopoietic stem cells or continuously repopulating epithelial cells from 
respiratory and intestinal tract.  
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AAV vectors preferentially transduce dividing cells. The fact that the transduction 
efficiency of ss and sc AAV vectors depends on cells in S/G2 phase (Franzoso et al., 
2017 (269)) may explain their low transduction efficiency in post-mitotic cells. However, 
sc AAV vectors may be preferred over ss AAV vectors in mitotically active cells as in 
contrast to ss vectors, they allow cell cycle progression through mitosis (Franzoso et al., 
2017 (269)).  
Taken together, the findings presented in this thesis on cell cycle preference of AAV2 
replication/gene expression and on the influence of cellular proteins on the transduction 
efficiencies of ss and sc AAV vectors furthers our knowledge on AAV biology and may 
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